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 Introduction: Alzheimer’s disease (AD) is a neurodegenerative disease that causes 
behavioural and cognitive impairments and is hallmarked by amyloid plaques and 
neurofibrillary tangles of the protein tau. There is currently no cure for AD, with 
currently available treatments only targeting symptoms. Murine models of AD, such 
as the APPSwe/PS1ΔE9 (APPxPS1) model, replicate important aspects of the disease 
and allow preclinical insights into the efficacy of other potential therapeutics. With 
evidence that targeting the endocannabinoid system may be therapeutic in AD, 
cannabidiol (CBD) has been of recent interest as to whether its anti-inflammatory, 
antioxidant and neuroprotective properties make it a potential therapeutic avenue for 
AD. In vitro and in vivo evidence shows that CBD indeed prevents and reverses AD-
related amyloid plaques and neurofibrillary tangles, and cognitive decline including 
social and object recognition deficits. This thesis aimed to evaluate the therapeutic 
potential of chronic treatment with low dose CBD (5 mg/kg bodyweight) to reverse 
the behavioural deficits of APPxPS1 transgenic mice. 
 Materials and Methods: 12-month-old control and transgenic female APPxPS1 
mice were treated daily (post-onset of AD-like symptoms) via intraperitoneal injection 
with 5 mg/kg bodyweight CBD (or vehicle) starting three weeks prior to the 
assessment of a variety of behavioural paradigms. Mice were tested for anxiety, 
exploration and locomotion in the light dark test, motor functions including 
coordination and balance in the pole test and accelerod paradigms, object recognition 
memory, spatial learning and memory in the cheeseboard test, and sensorimotor gating 
using the acoustic prepulse inhibition paradigm. 
 Results: APPxPS1 mice exhibited a hyper-locomotive phenotype in the light dark 
test, and CBD instigated more explorative-like behaviour in the dark zone in both 
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genotypes. All mice showed similar motor function, and similar spatial learning rates, 
although APPxPS1 mice took longer to complete the cheeseboard training (due to a 
lower locomotion speed). All mice had intact spatial memory and retrieval memory, 
although APPxPS1 mice showed reduced levels of perseverance in the cheeseboard 
probe trial. Importantly, vehicle-treated APPxPS1 mice were characterised by object 
recognition deficits, which CBD recovered without impacting on control mice. 
Finally, all APPxPS1 mice exhibited a prepulse inhibition deficit regardless of 
treatment condition.  
 Summary and Conclusion: APPxPS1 transgenic mice were hyper-locomotive and 
CBD elevated exploration in the dark zone of the light dark test. APPxPS1 females did 
not exhibit motor function deficits, and importantly CDB did not alter motor function 
in either APPxPS1 or control mice. Spatial learning and memory were not affected in 
APPxPS1 transgenic females. Importantly, 5 mg/kg CBD reversed novel object 
recognition deficits in APPxPS1 transgenic females suggesting a therapeutic-like 
effect in this established mouse model for AD. CBD did not reverse PPI deficits 
evident in transgenic females. Further research into the effects of CBD should consider 
investigating molecular mechanisms as well as testing other treatment designs 
including the consideration of other doses and ages of test animals. In conclusion, this 
study suggests that CBD has therapeutic value for particular behavioural impairments 
present in AD patients.  
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Chapter 1: Introduction 
1.1 Alzheimer’s disease 
 As a result of Australia’s ageing population, it is expected that by 2056 around 6.4 
million Australians will have been diagnosed with dementia, which is currently 
incurable and without effective preventative options (Brown, Hansnata & La 2017). 
Although dementia is not considered part of normal ageing, it primarily affects the 
elderly (AIHW 2012), with age being the most important risk factor (Chen & Mobley 
2019). As an umbrella term, dementia describes a group of neurodegenerative diseases 
characterised by the irreversible and progressive decline in cognitive skills, including 
impairments in language, memory, perception and personality. Accounting for up to 
75% of all cases worldwide, Alzheimer’s disease (AD) is the most common form of 
dementia, and, following coronary heart disease, dementia including AD was the 
second leading cause of death in Australia in 2017, especially among the elderly 
(AIHW 2019). It is predicted that without significant advancement in diagnostic and 
therapeutic technologies, the economic cost of the disease to the Australian health and 
aged care systems will exceed $1 trillion over the next four decades (Brown, Hansnata 
& La 2017).  
 AD is an insidious neurodegenerative disease that is caused by progressive damage 
to neuronal cells and results in varying concomitant symptoms related to the area of 
affected brain. Mild cognitive impairment (MCI) generally precedes AD, with an 
average of 32 % of individuals with MCI developing AD within 5 years (Alzheimer’s 
Association 2018). AD progresses from mild, to moderate and finally to severe AD. 
In the mild stage, AD is initially characterised by apathy, depression and mild deficits 
in short-term memory, spatial orientation, learning and communication. Occasionally, 
it can be difficult to distinguish these early signs of AD from typical age-related 
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cognitive changes (Alzheimer’s Association 2018). As AD progresses to moderate 
clinical stages, memory continues to decline and begins to affect everyday tasks 
including reading, writing, eating, dressing and bathing, and results in agitation, 
suspiciousness and loss of emotional control. Patients living with the late stages of the 
disease require full-time care, and have severe disturbances to cognitive abilities 
including disorientation, poor judgement, behavioural changes, severe impairments in 
speech and facial recognition, and susceptibility to secondary diseases. Ultimately, AD 
results in loss of bodily functions, difficulty speaking, swallowing and walking, and is 
fatal, commonly due to aspiration pneumonia, which is the result of a difficulty in 
swallowing combined with being bed-bound (Alzheimer’s Association 2018). 
 Diagnosis of AD is often difficult and requires a variety of diagnostic approaches 
including blood tests, physical and neurological examinations, brain imaging to 
determine the levels of AD-relevant markers, and consideration of medical and family 
history of patients. However, often a verified diagnosis can only be made post-mortem, 
and involves analysis of brain tissue, as the brain is the main organ affected in AD. A 
pathological hallmark of AD is the extracellular accumulation of amyloid-beta (Aβ) 
protein fragments around the neurons in the brain, which are the result of the aberrant 
cleavage of amyloid precursor protein (APP). These fragments form Aβ plaques that 
interfere with neuronal communication, which is thought to cause cell death and the 
signs and symptoms of AD (Alzheimer’s Association 2018). However, while amyloid 
burden is a cardinal feature of AD, there is no correlation between the amount of 
amyloid burden, and the severity or stage of AD (Chen & Mobley 2019). Another 
hallmark of AD is the intracellular accumulation of hyperphosphorylated microtubule 
associated protein tau (MAPT), forming neurofibrillary tangles (NFT) that block the 
transport of nutrients within neurons. Cerebral atrophy is also a very characteristic sign 
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of AD in post-mortem brains and is caused by neuronal cell death. Furthermore, 
microglial activation, oxidative stress and chronic inflammation of the brain are seen 
in AD patients due to the activation of the immune system in response to toxic Aβ 
plaques and NFTs (Alzheimer’s Association 2018). Damage to the brain of someone 
affected by AD on average starts 15 years before symptoms, which manifest once the 
brain is no longer able to compensate with the early damage. The neuropathology of 
AD and the roles of amyloid plaques and NFTs are further described in section 1.1.2. 
 AD seems to affect women disproportionately. Briefly, AD is significantly more 
common in women than men (Oveisgharan et al. 2018) and studies have found that 
women have poorer cognitive profiles than in men at the same stage of AD (Laws, 
Irvine & Gale 2016). Also, a recent study has found that women with AD have more 
NFTs and slightly more Aβ compared to men (Oveisgharan et al. 2018), demonstrating 
the presence of sex differences in AD pathologies. Briefly, it has been suggested that 
the sex differences seen in AD may be in part due to a reduction of estrogen in 
postmenopausal women, the greater cognitive reserve in men, and the influence of the 
apolipoprotein E e4 allele (a risk factor for AD, introduced below in section 1.1.1; 
Laws, Irvine and Gale (2016)). 
1.1.1 Genetics of AD 
 Presently, there are numerous categorisations of AD. Most often, AD is 
categorised as either early-onset familial AD (FAD) or late-onset sporadic AD (SAD), 
depending on the age of onset and the underlying cause and genetics. However, while 
the causes of FAD and SAD are dissimilar, the two are clinically and 
histopathologically indiscernible (Götz & Ittner 2008). Of SAD and FAD, late-onset 
SAD is the more common form of AD, with disease onset occurring at the age of 65 
years or older. The cause of SAD is still unclear, although risk factors for SAD 
 14 
including susceptibility genes and environmental factors have been identified. Some 
metabolic risk factors for SAD include hypertension, obesity and type 2 diabetes 
mellitus (Mendiola-Precoma et al. 2016). The most widely studied genetic risk factor 
for SAD is the gene encoding apolipoprotein E (APOE), which has been identified as 
a susceptibility gene in genome-wide association studies, as reviewed (Mendiola-
Precoma et al. 2016). APOE transports cholesterol in the blood and has three forms, 
the e2, e3 and the e4 form. All individuals inherit two copies of APOE. The e4 variant 
of the gene (APOE-e4) is the form associated with an increased risk of AD and is 
linked to developing AD at an earlier age of onset compared to individuals possessing 
the e2 and e3 variants. Possessing one copy of APOE-e4 results in a three times higher 
chance of developing AD compared to someone with two copies of the e3 variant (the 
most common variant), while possessing two copies of APOE-e4 increases this risk to 
8 to 12 times. Those possessing the e2 variant may have a decreased risk of developing 
AD compared to those possessing the e3 form (Alzheimer’s Association 2018). It is 
important to note that inheritance of the APOE-e4 gene does not cause AD, it merely 
increases ones risk of developing the disease (Alzheimer’s Association 2018; 
Mendiola-Precoma et al. 2016). 
 Early-onset FAD is less common than SAD and is estimated to represent less than 
1% of all AD cases. FAD results from the inheritance of an autosomal dominant 
mutation in the genes encoding APP, presenilin 1 (PS1) or presenilin 2 (PS2), the latter 
two being enzymes participating in the processing of APP. Inheritance of AD-relevant 
mutations in APP or PS1 guarantees the disease, while inheritance of a mutation in 
PS2 results in a 95% chance of developing AD (Alzheimer’s Association 2018). To 
date, 52 APP mutations (26 duplication mutations and 26 missense mutations; Julia 
and Goate (2017)), over 180 PS1 mutations and around 10 PS2 mutations have been 
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linked to AD. Individuals that inherit any of these three AD-relevant mutations often 
develop symptoms of AD before the age of 65, usually in their 40’s or 50’s, but 
sometimes as early as 30 years of age, hence the term early-onset FAD. Mutations in 
APP, PS1 and PS2 result in the aberrant cleavage of APP into Aβ peptides of 40 
residues (Aβ40) or of 42 residues (Aβ42), which are thought to form toxic Aβ plaques 
responsible for causing neuronal cell death (Alzheimer’s Association 2018). This is 
further discussed in section 1.1.2.  
 Other than SAD and FAD, AD can also be categorised in other ways. Young-onset 
AD, which is distinct from early-onset FAD, results in disease development before the 
age of 65 without any known genetic risk factor or family history present (Chen & 
Mobley 2019), i.e. young-onset AD is sporadic while FAD is the result of the 
inheritance of a mutation, however both result in disease development before the age 
of 65 years. In other words, young-onset AD is similar to late-onset SAD in that it is 
sporadic, however it is seen in people of a much younger age than those with SAD. 
Furthermore, AD can also be seen in Down syndrome (known as AD-DS), where 50% 
of individuals with Down syndrome develop AD within their lifetime. The extra copy 
of chromosome 21, which contains the gene for APP, results in the production of more 
wild type levels of the protein and Aβ fragments in Down syndrome individuals, 
leading to AD-DS (Alzheimer’s Association 2018; Chen & Mobley 2019). 
1.1.2 Neuropathology of AD  
  There are numerous hypotheses as to the pathological course of AD, and the role 
of mutations in APP, PS1 and PS2 in AD. The amyloid cascade hypothesis, first 
proposed by Hardy and Higgins (1992), has been the most prominent hypothesis in 
explaining the cause of AD, and suggests that the deposition of Aβ is the initial 
pathological event in AD, which then leads to amyloid plaques, NFT and eventually 
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dementia (Reitz 2012). It can be summarised as follows (Figure 1): mutations in APP, 
PS1 or PS2 result in increased Aβ production, which leads to oligomerisation of Aβ42 
and plaque formation. This leads to microglial activation and progressive injury to 
neurons and synapses, which then cause altered homeostasis of neurons and oxidative 
injury. The activity of phosphatases and kinases becomes altered and leads to NFT, 
which finally leads to widespread neuronal dysfunction and cell death, resulting in 
dementia (Julia & Goate 2017). The neuropathological components of AD implicated 
in the amyloid cascade hypothesis are further discussed below. 
 
 17 
    
Figure 1: The amyloid cascade hypothesis. The proposed sequence of pathogenic 
events leading to AD. The amyloid cascade hypothesis begins with mutations in 
amyloid precursor protein (APP), presenilin 1 (shown as PSEN1) or presenilin 2 
(shown as PSEN2) that cause accumulation of amyloid-beta (Aβ) and initiate a cascade 
that leads to dementia. Abbreviation: Amyloid-beta peptide of 42 residues (Aβ42). 
Image from Julia and Goate (2017).  
 
 
 As mentioned, extracellular plaques consisting of deposited Aβ peptides are a key 
pathological sign of AD; these plaques are thought to be neurotoxic and interfere with 
neuronal communication, and are thought to be the result of the aberrant splicing of 
APP. APP is a transmembrane protein found in cells throughout the body and is 
encoded by APP on chromosome 21, which consists of 18 exons that are alternatively 
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spliced to produce APP proteins that are between 695 and 770 amino acids in length 
(Julia & Goate 2017). APP is sequentially cleaved by the enzymes α-, β- and γ-
secretases, in two principle pathways: the non-amyloidogenic pathway (Figure 2A) 
and the amyloidogenic pathway (Figure 2B). The majority of APP processing in the 
healthy brain is via the non-amyloidogenic pathway, which involves the cleavage of 
APP by α-secretase. This forms an extracellular N-terminal fragment known as soluble 
APP alpha (sAPPα), and a cell membrane bound C-terminal fragment known as αCTF. 
αCTF is then cleaved by γ-secretase, producing the APP intracellular domain (AICD), 
which regulates gene transcription, and the extracellular P3 peptide. PS1 and PS2 
encode the catalytic components of γ-secretase. The alternate and less common 
pathway, the amyloidogenic pathway, is involved in the generation of amyloid 
peptides. This occurs by cleavage of APP by β-secretase, forming the extracellular 
soluble APP alpha fragment (sAPPβ) and the C-terminal fragment beta (βCTF). γ-
secretase then cleaves βCTF to produce AICD and extracellular plaque-forming Aβ 
peptides (Chen & Mobley 2019). The amyloid peptides produced in the amyloidogenic 
pathway vary in length, as the site of γ-secretase cleavage is promiscuous (Julia & 
Goate 2017). The majority of amyloid peptides formed in the amyloidogenic pathway 
are 40 amino acids long (Aβ40), with around 10% of peptides being 42 residues long 
(Aβ42). Aβ42 peptides more readily aggregate into fibrils and plaques (Julia & Goate 
2017) due to the C-terminal isoleucine and alanine residues that give this peptide 
hydrophobic properties. For this reason Aβ42 is predominately found in cerebral 
plaques in AD (Chen & Mobley 2019). 
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Figure 2A-B: Amyloid precursor protein (APP) processing. 
A) The non-amyloidogenic pathway is the major processing pathway of amyloid 
precursor protein (APP) and B) the amyloidogenic pathway that results in the 
production of amyloid beta (Aβ) peptides. Scissor icon represents a secretase enzyme. 
Abbreviations: Amyloid precursor protein intracellular domain (AICD), alpha C-
terminal fragment (αCTF), beta C-terminal fragment (βCTF), P3 peptide (P3), soluble 
amyloid precursor protein alpha (sAPPα), soluble amyloid precursor protein beta 




 Mutations in APP, PS1 and PS2 seem to influence the overproduction of the more 
toxic Aβ42. For example, pathogenic missense mutations close to the cleavage sites of 
β- or γ-secretases within or immediately flanking the Aβ domain of APP (encoded by 
exons 16 and 17) can result in either i) overall elevated production of Aβ peptides, ii) 
mutated Aβ peptides that form fibrils faster than wild type peptides, or iii) impaired 
secretase cleavage and increased hydrophobicity of the produced Aβ peptides, all of 
which are associated with aggregation of the peptides and the formation of AD-
characteristic plaques. Missense mutations can also cause increased deposition of Aβ40 
in vascular walls, which is associated with significant cerebral amyloid angiopathy and 
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haemorrhagic stroke (Julia & Goate 2017). Further, a double mutation in exon 16 of 
APP in a Swedish family of FAD appears to result in a higher production of both Aβ40 
and Aβ42 (Julia & Goate 2017). Other mutations in APP seem to be protective of AD 
and confirm the role of amyloid deposition in the pathogenesis of AD, which is 
currently debated. For example, an alanine-to-threonine substitution adjacent to the β-
secretase cleavage site in APP results in approximately a 40% reduction in the 
formation of Aβ peptides in vitro as this mutation prevents cleavage of APP by β-
secretase, thereby shunting APP processing into the non-amyloidogenic pathway, 
reducing Aβ aggregation, and thus reducing the risk of AD (Julia & Goate 2017).  
 How mutations in PS1 and PS2, encoding the catalytic core of γ-secretase, 
contribute to the cause of AD is still poorly understood, with both toxic gain-of-
function and loss-of-function hypotheses being investigated. Regardless of the 
function of the mutation, in vivo and in vitro paradigms have shown that FAD-relevant 
PS1 and PS2 mutations seem to increase the relative amount of the toxic Aβ42 versus 
Aβ40 in many but not all cases, which is more likely due to decreasing the total amount 
of Aβ40 rather than increasing the total amount of Aβ42 (Chávez-Gutiérrez et al. 2012; 
Kelleher & Shen 2017).  
 While the amyloid cascade hypothesis implicates amyloid plaques as the 
neurotoxic initiator of AD, there is debate as to whether these plaques are indeed 
damaging, or whether they are actually a neuroprotective adaptation (Zhou et al. 2018). 
It has been argued that the historical data that scientists have used to conclude that Aβ 
plaques are neurotoxic, could also support the converse idea that disease in AD, for 
example cellular stress, leads to increased Aβ as a protective function; i.e. amyloid 
plaques may be a response to AD, not the cause (Lee et al. 2004). Evidence for this is 
the fact that cellular stress decreases in response to increased Aβ, and that Aβ can act 
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as a superoxide dismutase (Lee et al. 2004). Additional evidence for this challenge to 
the dogma includes the fact that Aβ does not correlate with cognitive decline in AD, 
that Aβ occurs late in the pathogenesis of AD, that there is no evidence for amyloid 
toxicity in vivo (only in vitro), and the suggestion that the increase in Aβ associated 
with genetic mutations linked to AD could be explained as “mutation leads to disease 
leads to increased amyloid-β” (Lee et al. 2004). As a result, it is now generally agreed 
that rather than amyloid plaques, it is soluble dimers of Aβ that are neurotoxic (Zhou 
et al. 2018). From this comes the idea that the accumulation and sequestration of 
soluble Aβ via the amyloid plaques might be the body’s protective mechanism to 
reduce the toxic forms in the brain (Treusch, Cyr & Lindquist 2009). It is therefore 
important to note that if amyloid plaques are a protective adaptation in AD, then 
therapies designed to reduce plaque formation could be detrimental. Nevertheless, 
regardless of the toxicity or function of amyloid plaques, they are one of a few distinct 
hallmark features of AD.  
 Neuroinflammation is also seen in AD. Microglia, the resident macrophage-like 
immune cells of the central nervous system (CNS), are noticeable in areas of 
neurodegenerative damage in AD. Microglia are activated in response to receptor 
ligation to Aβ, and in the healthy brain microglia clear Aβ before plaque formation 
begins via phagocytosis of Aβ and through secretion of pro-inflammatory cytokines 
and chemokines such as tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). 
In AD, microglia are unable to completely clear the area of Aβ due to incapable 
phagocytic abilities, possibly due to the down-regulation of Aβ phagocytosis receptor 
expression (Heneka et al. 2015). This results in a build-up of Aβ, microglia and 
inflammatory cytokines in affected brain regions. This prolonged microglial activation 
and persistent exposure to pro-inflammatory cytokines leads to neuroinflammation 
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which may also be itself a pathological contributor to AD. This process causes 
functional and structural damage to neurons, with neuronal debris leading to 
perpetuation of inflammation, which exacerbates disease progression (Heneka et al. 
2015). It is thought that perpetuation of these processes over time may lead to the 
irreversible senescence of microglia (Heppner, Ransohoff & Becher 2015).  
 In addition, impairments to glutamatergic and cholinergic signalling are seen in 
AD, both of which are involved in learning and memory processes, as reviewed 
(Parsons et al. 2013). The release of cytokines TNF-α and IFN-γ during prolonged 
microglial activation at Aβ plaque sites in AD create an excito-neurotoxic state, which 
leads to further neurodegeneration and induces the release of the excitatory 
neurotransmitter glutamate. This leads to the overstimulation of N-methyl-D-aspartate 
(NMDA) receptors and to the subsequent sustained influx of calcium ions. This 
increase in calcium creates a pathological “background noise” that impairs signalling 
cascades leading to impaired long-term potentiation and thereby impaired learning and 
memory (Parsons et al. 2013). Increased calcium also leads to elevated production of 
nitric oxide (NO), which inhibits energy production by mitochondria, thereby leading 
to impaired neuronal function and neurodegeneration at regions of microgliosis (at Aβ 
plaque sites). Increased NO, and other reactive oxygen species (ROS), cause oxidative 
damage to neurons at these sites as the antioxidant systems are overwhelmed and no 
longer able to mediate the effects of ROS in AD (Takeuchi 2010). This leads to altered 
oxidative homeostasis and oxidative stress, which is thought to contribute to the 
downstream hyperphosphorylation of tau. Furthermore, AD causes the degeneration 
of cholinergic neurons in the basal forebrain, which have projections in areas of the 
brain important for memory including amygdala, hippocampus and frontal cortex 
(Schliebs & Arendt 2011). This leads to long-term disruption to acetylcholine (ACh) 
 23 
neurotransmission and contributes to cognitive impairment, as ACh is an essential 
CNS neurotransmitter involved in cognition, learning and memory (Parsons et al. 
2013). Numerous post-mortem studies demonstrate that the decline in ACh levels that 
contribute to cognitive decline in AD are linked to the decrease of choline 
acetyltransferase activity (which is involved in the synthesis of ACh), decreases in 
ACh release, decreases in nicotinic and muscarinic ACh receptor binding and perhaps 
alterations to acetylcholinesterase (AChE; the enzyme involved in ACh metabolism) 
activity, as reviewed (Auld et al. 2002; Lombardo & Maskos 2015; Parsons et al. 2013; 
Schliebs & Arendt 2011). Disruptions to glutamatergic and cholinergic signaling in 
AD are important factors in the current treatment strategies for AD, discussed further 
in section 1.1.3. 
 Another key pathological sign of AD is the occurrence of NFTs, which are 
composed primarily of tau (MAPT), encoded by the MAPT gene. In a healthy cell, tau 
is involved in cytoskeletal stabilisation and promotes the formation of microtubules, 
which is achieved through phosphorylation of 2-3 tau residues. However, in AD, tau 
becomes hyperphosphorylated and aggregates together, forming NFTs. This resulting 
pathology is neurotoxic and linked to neurodegeneration, not only due to the formation 
of insoluble intracellular fibrils, but also due to the reduced affinity of tau to bind to 
microtubules, resulting in a destabilised cytoskeleton and reduced axonal transport of 
organelles and biomolecules (Shepherd, McCann & Halliday 2009). Although there 
are currently no mutations in MAPT that are linked to AD, mutations in MAPT are 
indeed associated with the cause of another dementia, frontotemporal dementia (FTD). 
Like AD, FTD is characterised by NFTs, and transgenic animal models of FTD 
expressing mutations in MAPT demonstrate that NFTs induce cognitive deficits, 
indicating that NFTs are linked to cognitive decline in dementia (Eersel et al. 2015). 
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Also, transgenic models of tau pathology develop NFTs in the absence of amyloid 
pathology, indicating that amyloid pathology in AD may induce NFTs, but NFTs do 
not induce amyloid pathology, congruent with the amyloid cascade hypothesis and the 
suggestion that tau pathology occurs downstream of amyloid pathology (Kitazawa, 
Medeiros & M LaFerla 2012). Furthermore, tau pathology is more commonly seen in 
later stages of AD (Kuret et al. 2005).  
1.1.3 Treatment of AD 
 There is currently no cure for AD, and with only a limited number of therapeutic 
options currently available that act to treat the symptoms of the disease, there is a dire 
need for more research into possible therapies to prevent, treat and cure the disease. 
Currently available treatments include three AChE inhibitors and one NMDA receptor 
antagonist that only provide symptomatic relief to patients in early disease stages 
without altering disease progression and also have numerous side effects. Rather than 
only treating symptoms of AD, treatments that focus on targeting the pathology of AD 
would be more beneficial in the attempt to treat and cure the disease. Indeed, clinical 
trials are currently underway to investigate the potential of aetiology-based treatments 
that aim to block the generation of the toxic amyloid and tau pathologies associated 
with the progression of AD (Cummings et al. 2019). Furthermore, complementary 
preventative treatments aiming to manage comorbidities and advise healthy lifestyles 
including advice on diet, cognitive stimulation and exercise are being investigated 
(Mendiola-Precoma et al. 2016).  
 Four approved pharmacological therapies are available and as mentioned only treat 
the symptoms of the disease without preventing or reversing the disease pathology. 
Memantine, a non-competitive NMDA receptor antagonist is used to inhibit the 
glutamatergic system to reduce cell death and has been approved for those with 
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moderate or severe AD. However, side effects such as dizziness, fatigue, vomiting and 
high blood pressure have been reported, and the effectiveness of the drug reduces after 
a few years (Wong 2016). Donepezil, rivastigmine and galantamine are AChE 
inhibitors, which prevent the loss of ACh from neurons and improve the cognition and 
daily life of those with mild to moderate AD. Again, these are associated with side 
effects such as diarrhoea, vomiting, nausea, dizziness, insomnia and fatigue, as 
reviewed (Wong 2016). Clinical observations indicate that the complementary 
mechanisms of memantine and AChE inhibitors confers potential for their use in 
combination, with preclinical studies showing that combination therapy can produce 
greater improvements in memory than either treatment alone, as reviewed in Parsons 
et al. (2013). 
 As mentioned, clinical trials investigating disease-modifying treatments are 
currently underway and are based on the amyloid cascade hypothesis. These initiatives 
focus on preventing amyloid burden by targeting secretase activity or binding amyloid, 
but also evaluate the potential of preventing NFT by targeting the kinases involved in 
the hyperphosphorylation of tau. For example, metalloproteinases that upregulate and 
stimulate 𝛼-secretase and the non-amyloidogenic pathway are being investigated. γ-
secretase inhibitors and modulators have also been investigated, although inhibitors in 
past clinical trials have induced severe side effects (Mendiola-Precoma et al. 2016). 
Furthermore, inhibitors of Aβ aggregation, sequesters of Aβ monomers and biological 
products involving microglia-mediated clearance of amyloid have reached clinical 
trials, as reviewed extensively (Mendiola-Precoma et al. 2016).  
 As mentioned earlier, non-pharmacological treatments to prevent AD are also 
being investigated. Lifestyle strategies including exercise, cognitive stimulation, 
restriction of calories and increased socialisation, as well as diet strategies including 
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vitamin and probiotic supplementation, restricted alcohol consumption (excluding low 
levels of red wine consumption), consumption of flavonoids, alkaloids, or terpenoids 
and inclusion of the Mediterranean and Asiatic diets, have been thought to be 
beneficial in preventing AD, especially in combination (Mendiola-Precoma et al. 
2016). Randomised controlled trials investigating exercise and cognitive stimulation 
have especially shown that these lifestyle modifying strategies improve cognition, but 
larger trials are still required and are especially lacking for diet related strategies, as 
reviewed (Alzheimer’s Association 2018; Mendiola-Precoma et al. 2016).   
 
1.2 Transgenic mouse models of AD 
 Numerous in vitro and in vivo models of AD exist, each with merits and 
disadvantages in studying the disease and the evaluation of new therapeutic targets. Of 
importance to this study are transgenic murine models of AD, which demonstrate 
genetic, pathological and/or symptomatic changes relevant to AD, enabling their use 
as models in the study of the aetiology, pathophysiology, diagnosis and treatment of 
the disease (Elder, Gama Sosa & De Gasperi 2010). Although the majority of AD 
patients develop SAD and therefore do not carry mutations in APP, PS1 or PS2, most 
transgenic murine models of AD actually model FAD, due to the ability to recapitulate 
amyloid pathology through the use of dominant mutations identified from FAD 
(Jankowsky & Zheng 2017). Therefore, single and double transgene expression of 
differing FAD-associated mutations in APP, PS1 and PS2 genes form the basis of the 
generation of the majority of transgenic mouse models for AD, which can then be used 
to assess amyloid pathology, which is relevant for both SAD and FAD. Furthermore, 
modelling SAD is challenging due to the sporadic nature of the disease, limiting most 
animal models of AD to transgenic murine models of FAD (Jankowsky & Zheng 
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2017). Mutations in the MAPT gene are also utilised to generate transgenic models of 
dementia to assess tau pathology. Most often, behavioural tests assessing social 
behaviours, short-term and long-term memory including recognition memory and 
spatial learning and memory, associative learning, anxiety, exploration, locomotion 
and sensorimotor gating are employed to assess AD-relevant behaviours in these 
models. Neuropathological analyses are also used to investigate molecular changes in 
the brain that are relevant to the mechanisms involved in AD.   
1.2.1 APPSwe/PS1ΔE9 double transgenic mouse 
 Of the transgenic mice that have been generated to model FAD, the double 
transgenic APPSwe/PS1ΔE9 (APPxPS1) mouse model was of particular interest for 
this thesis. Dr. David Borchelt from the University of Florida was the first to generate 
APPxPS1 mice, which carry two FAD-associated mutations; the chimeric 
mouse/human APP gene with Swedish mutation (Mo/HuAPP695swe/Swedish 
mutations K595N/M596L) and the mutant human PS1 gene with exon 9 deletion 
(PS1/ΔE9 (Borchelt et al. 1997; Jankowsky et al. 2004a; Jankowsky et al. 2004b)). 
Both transgenes were co-injected at a single locus on chromosome 9 and are controlled 
by the mouse prion promoter, which directs transgene expression mostly to CNS 
neurons. This model was generated on a mixed congenic C57BL/6JxC3H/HeJ 
background and is maintained as a hemizygote. The APPSwe mutation was introduced 
by replacing the mouse DNA sequence encoding for three amino acid residues within 
the Aβ domain with the human sequence, which was then modified to encode the 
human Swedish mutation. The inserted human PS1/ΔE9 mutation expressed in high 
levels displaces detectable endogenous mouse protein. Together, these two transgenes 
elevate the amount of Aβ produced by favouring the amyloidogenic pathway, and as 
a double transgene model exhibit accelerated amyloid pathology in comparison to 
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single transgene mouse models (Borchelt et al. 1997; Jankowsky et al. 2004a; 
Jankowsky et al. 2004b). Further, it is suggested that the PS1/ΔE9 mutation causes the 
preferential cleavage of APP C99 at residue 42, causing the specific elevation of Aβ42 
levels and unaltered Aβ40 levels (Jankowsky et al. 2004a).  
 As a result of the combination of the APPSwe and PS1/ΔE9 transgenes, the 
APPxPS1 model is considered a particularly aggressive model of amyloid pathology 
(Garcia-Alloza et al. 2006), and is commonly used as a model of AD, or more 
specifically, of FAD. This model exhibits AD-like amyloid pathology, with Aβ 
plaques appearing as early as 4 to 6 months and accumulating with age (Garcia-Alloza 
et al. 2006; Hamilton & Holscher 2012; Jankowsky et al. 2004b; Ruan et al. 2009; 
Savonenko et al. 2005). APPxPS1 mice exhibit higher levels of soluble Aβ40 and Aβ42 
compared to control mice. The levels of these soluble peptides increase with age, with 
female APPxPS1 mice showing significantly higher levels of soluble Aβ40 and Aβ42 
compared to male APPxPS1 mice (Wang et al. 2003). Furthermore, activated 
microglia and astrocytes are evident in both the hippocampus and neocortex of 
APPxPS1 mice beginning at 4 months of age (microglia), and beginning at 6 months 
of age (astrocytes), and are found in close association with Aβ plaques (Ruan et al. 
2009).  
 APPxPS1 mice exhibit a range of behaviours relevant to the study of AD, many of 
which have been shown to be associated with the pathological changes seen in the 
brains of the transgenic mouse model. For example, APPxPS1 mice have been shown 
to exhibit spatial learning and memory deficits in the Morris water maze (MWM) and 
long-term contextual memory deficits in the step down passive avoidance test, which 
are correlated with hippocampal and cortical levels of soluble Aβ40 and Aβ42 
(Savonenko et al. 2005; Zhang et al. 2011). Other studies have also demonstrated that 
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the APPxPS1 mice have impairments in spatial learning, spatial task acquisition and 
spatial memory in paradigms other than the MWM, including the hidden target version 
of the Barnes maze and in the cheeseboard (CB) paradigm, resembling the symptoms 
of spatial disorientation seen in some patients with AD (Cheng et al. 2014b; O’Leary 
& Brown 2009). APPxPS1 mice also exhibit task-dependent hyper-locomotion and 
anxiolytic-like phenotypes in the light dark (LD) test at 7 months of age, reminiscent 
of the restlessness and agitation seen in AD patients (Cheng et al. 2013; Cheng et al. 
2014b). Some studies also report disinhibitory-like behaviours in the elevated plus 
maze (EPM), and social and object recognition impairments in the social 
preference test and novel object recognition task (NORT; Cheng et al. 2013; Cheng 
et al. 2014a; Cheng et al. 2014c; Lalonde, Kim & Fukuchi 2004).  
To be useful as an animal model of human disease, a transgenic mouse model must 
display all of the following for the disease in question; face validity, construct validity 
and predictive validity. Face validity refers to the model possessing the essential 
pathological, physiological and behavioural features or symptoms relevant to the 
disease (Elder, Gama Sosa & De Gasperi 2010; Nestler & Hyman 2010). For example, 
the APPxPS1 model displays the AD-relevant pathological hallmarks including 
amyloid plaques and NFT, and AD-relevant cognitive and motor impairments 
including spatial disorientation and recognition impairments. Construct validity refers 
to the similarity between human and mouse disease origin, i.e. the mouse model is to 
mimic the underlying cause of the disease (or aspects thereof; van der Staay, Arndt 
and Nordquist (2009). For example, as a model for FAD, APPxPS1 mice are generated 
through genetic techniques that result in mutations in the genes APP and PS1, which 
are two of the three major mutations associated with the cause of FAD. Finally, 
predictive validity suggests that the model will respond to pharmacological therapy in 
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a similar manner to humans with the disease (Nestler & Hyman 2010). Memantine, a 
common therapy for AD, has been found to reduce the cortical levels of soluble Aβ42 
and increase the ratio of Aβ40 /Aβ42 in the brains of APPxPS1 mice (Alley et al. 2010).  
 
1.3 Medicinal Cannabis 
 The plants Cannabis sativa and Cannabis indica are the two most common species 
found in the drug cannabis (marijuana), which has a long history of human use (Lim, 
See & Lee 2017). Cannabis has long been known for its fibrous, psychotropic and 
medicinal properties and has been utilised for rope, food, recreation, religious rituals, 
and in medicine. Numerous cultures have recorded the medical use of cannabis for a 
range of ailments including pain, muscle spasms and malaria, starting with the Chinese 
as far back 2900BC, where cannabis is listed in the father of Chinese medicine, 
Emperor Shen Nung's, pharmacopoeia (Hill et al. 2017).  
 While the medical properties of cannabis have long been known to ancient 
civilizations, the introduction of medicinal cannabis to Western medicine has been 
only recent. Irish doctor Sir William Brooke O'Shaughnessy discovered that cannabis 
could treat nausea and pain in cholera patients and reported that cannabis stopped 
convulsions in a child while studying in India in the 1830s (reviewed in Zuardi (2006)). 
By the 1890s, cannabis extracts were sold in pharmacies across Europe and the United 
States of America as a therapy for an assortment of ailments, with over 100 
publications printed on medicinal cannabis (reviewed in Hill et al. (2017)). The 1900s 
saw a decline in the use of medicinal cannabis due to legal restrictions and issues 
obtaining plants of consistent potency. However, the isolation and identification of the 
chemical structures of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), two of 
the major phytocannabinoids found in the plant, and the identification of cannabinoid 
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receptors in the brain and of an endogenous cannabinoid system in the latter half of 
the 20th century sparked an increase in scientific interest for cannabis (Zuardi 2006). 
Since, the effectiveness and safety of medicinal cannabis has become a focus of 
scientific research and medicinal cannabis use is on the rise in Australia today. 
However, while there is copious anecdotal evidence for the efficacy of cannabis as a 
therapy for an array of conditions, the scientific evidence is still limited due to the 
historical difficulty in obtaining quality plant material owing to criminalisation of the 
plant in many countries. 
 The cannabis plant, which originated in Asia and has since spread globally, has a 
controversial history with legal, ethical and social implications of cannabis use 
restricting the scientific research of the drug as a therapeutic up until recent times. 
Most significant are the policies enacted in the United States of America, including 
the Marijuana Tax Act of 1937 and the Controlled Substances Act of 1970, which 
restricted and later prohibited cannabis. The criminalisation and listing of cannabis as 
a Schedule I drug (considered to have a high potential for abuse and no medical 
properties) has complicated the research of medicinal cannabis further, as procurement 
of cannabis for academic purposes was limited (Bridgeman & Abazia 2017). In more 
recent times, the legalisation of medicinal cannabis has opened the doors to civilian 
use of the medicine and importantly, lesser restrictions on research. Canada legalised 
medicinal cannabis in 2001 and recently legalised recreational cannabis and is at the 
forefront of research, with back logs of licence applications by researchers 
demonstrating the extent of research in the country (Shir & Häuser 2019; Wadman 
2019). Legalisation of medicinal cannabis in individual US states (California in 1996) 
and in other countries such Australia, has also been important in the research of 
medicinal cannabis (Bridgeman & Abazia 2017).      
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 Today, medicinal cannabis is a term applied to whole plant material, cannabis 
extracts, purified plant constituents (e.g. the cannabinoids THC and CBD), or 
particular derivatives, which are used to treat diseases and relieve disease symptoms 
(Lim, See & Lee 2017). Recent legalisation of medicinal cannabis has given rise to 
companies selling whole plant material and extracts, labelled as medicinal cannabis, 
as well as companies more interested in developing pharmaceutical-derived cannabis 
products, forming a commercial medicinal cannabis market. Several companies have 
produced multiple drugs derived from cannabis, including Sativex® (a 1:1 CBD:THC 
drug marketed by GW Pharma), Epidiolex® (liquid extract of CBD marketed GW 
Pharma), and synthetic THC products dronabinol (marketed as Marinol® by AbbVie) 
and nabilone (marketed as Cesamet® by Valeant Pharmaceuticals International Inc), as 
reviewed previously (Mintz 2015). However, there are also numerous other analogues 
of cannabinoids and endocannabinoids that have been designed to be more 
enantiomerically pure, more metabolically stable and more potent than naturally 
derived constituents, including “HU-211” and “CT3” (Di Marzo, Bifulco & De 
Petrocellis 2004). Aside from synthetic analogues, pure constituents of cannabis are 
also used in clinical trials. For example, the purified cannabis constituent CBD has 
garnered much attention in the scientific community recently and is central to my 
Master of Research project. However, before a more in-depth examination of CBD 
carried out in section 1.3.2, a brief insight into the endocannabinoid system (ECS) 
must be considered.    
1.3.1 The endocannabinoid system (ECS) 
 The ECS is the endogenous cannabinoid system involved in numerous basic 
functions of the human body including learning, memory, neuronal development, pain 
sensation, inflammation, appetite, digestion, thermogenesis, the sleep-wake cycle, 
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mood and addiction. Cannabinoid receptors, endogenous cannabinoids 
(endocannabinoids) and various enzymes involved in the biosynthesis or degradation 
of the endocannabinoids make up the ECS. (Aizpurua-Olaizola et al. 2017; Di Marzo, 
Bifulco & De Petrocellis 2004).  
 Cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) are the two main 
G-protein-coupled receptors of the ECS, to which cannabinoids bind to affect their 
function. CB1 are highly abundant and found mostly in neurons, glial cells and many 
peripheral cells. They are highly expressed in the basal ganglia, cerebellum, 
hippocampus and the dorsal primary afferent spinal-cord regions, accounting for the 
effect of cannabis on motor coordination, learning and memory and pain regulation. 
Furthermore, CB1 are found at low concentrations in the brain stem, which accounts 
for the lack of acute fatalities (Baker et al. 2003). CB2 are found in immune cells such 
as B and T lymphocytes, macrophages and microglia, suggesting that the ECS has a 
role in immunomodulation and mediation of neuroinflammation, as reviewed (Stella 
2010). Activation of CB1 is responsible for the psychoactivity of cannabinoids, while 
activation of CB2 is not (Ramírez et al. 2005). 
 The two most well-known endocannabinoids are arachidonoylethanolamide 
(anandamide) and 2-aracidonoylglycerol (2-AG), which are biosynthesised when 
required by phosphodiesterase enzymes from membrane-associated fatty-acid 
precursors. These endocannabinoids then bind to and stimulate CB1 and CB2 second 
messenger pathways, mainly to regulate neurotransmission, and are then degraded 
through reuptake and hydrolytically cleaved by fatty acid amide hydrolase (FAAH; 
metabolises anandamide) or monoacylglycerol lipase (metabolises 2-AG). 
Anandamide and 2-AG are degraded to compounds that do not have cannabinoid 
receptor binding activity, such as arachidonic acid (Baker et al. 2003). The most well-
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known exogenous cannabinoids include the plant-derived phytocannabinoids THC 
and CBD and the synthetic cannabinoids CP 55,940 and WIN 55,212-2 (Karl, Garner 
& Cheng 2017). These exogenous cannabinoids can bind to cannabinoid receptors and 
therefore stimulate the ECS, presenting a potential therapeutic opportunity discussed 
further below. 
 The characteristic “on-demand” biosynthesis of endocannabinoids gives the ECS 
an adaptive response to changing conditions and the ability to restore homeostasis. 
However, in diseases such as AD, the ECS has been shown to be altered and associated 
with disease symptoms and progression, with post-mortem, in vitro and in vivo 
analyses having found dysregulated expression of some components of the ECS 
(Aizpurua-Olaizola et al. 2017). For example, a recent post-mortem study found that 
midfrontal and temporal cortex tissue from AD patients had significantly lower levels 
of anandamide compared to controls, which was inversely correlated to Aβ42 levels 
(but not Aβ40 or plaque load) and cognitive symptoms (Jung et al. 2012). Others have 
found that FAAH and CB2 were upregulated in microglia found proximal to plaque 
associated areas of post-mortem AD hippocampus tissue, with CB1 levels unchanged 
compared to controls (Benito et al. 2003; Mulder et al. 2011). Furthermore, in vitro 
and in vivo models provide additional evidence that the ECS is disrupted in AD. For 
example, in a microglial model, stimulation of CB2 with synthetic cannabinoids 
resulted in enhanced Aβ phagocytosis, and treatment with particular cannabinoids 
blocked Aβ induced activation (Ramírez et al. 2005). Further, stimulation of CB2 with 
specific CB2 agonists is capable of inducing the removal of Aβ from human frozen 
tissue sections by macrophages (stimulation with JWH-015; Tolón et al. (2009)), and 
of inducing cognitive impairment and a reduction in microglial activity in APPxPS1 
mice (stimulation with JWH-033; Aso et al. (2013)). Other studies have identified 
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increased levels of CB2 and 2-AG, and decreased levels of CB1 and anandamide, in 
rats treated with Aβ42 (Esposito et al. 2007a). Furthermore, the expression of CB1 has 
been found to be upregulated in the prefrontal cortex (PFC), amygdala and dorsal 
hippocampus, and downregulated in the ventral hippocampus of 6 and 12-month-old 
3xTg-AD mice (a triple transgenic mouse model of AD with mutations in APP, PS1 
and MAPT; Bedse et al. (2014)). Also, genetic deletion of CB2 in APPxPS1 mice 
results in reduced levels of microglia, infiltrating macrophages, pro-inflammatory 
chemokines and cytokines, and a reduction in soluble Aβ (Schmöle et al. 2015), 
whereas genetic deletion of CB1 in APPxPS1 mice accelerates memory impairment in 
the two-object recognition test (Aso, Andrés-Benito & Ferrer 2018). Thus, the 
involvement of the ECS in AD is complex and the ECS has been recognised as a 
potential therapeutic target for AD interventions.  
1.3.2 Cannabidiol (CBD) 
 CBD is the main non-toxic (non-“high” producing) phytocannabinoid of the plant 
C. sativa and is known to possess antioxidant, anti-apoptotic, neuroprotective, 
immunosuppressive and anti-inflammatory properties. Accordingly, numerous studies 
demonstrate a variety of pharmacological properties of CBD, including anti-
convulsive, anti-anxiety, anti-psychotic, anti-emetic, anti-inflammatory and anti-
rheumatoid arthritis (reviewed in Karl, Garner and Cheng (2017)). Also, CBD has very 
low toxicity and high lipophilicity, meaning it is readily able to cross the blood-brain 
barrier. CBD may have properties enabling it to reduce amyloid and tau pathologies, 
and unlike other cannabinoids does not impair cognition (Karl, Garner & Cheng 2017). 
These properties suggest that CBD may be relevant for the treatment of 
neurodegenerative diseases, especially AD. 
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 CBD has low affinity for cannabinoid receptors, especially compared to other 
cannabinoids such as THC, and likely exerts its effect on the ECS as a non-competitive 
antagonist of CB1 and CB2 agonists. This may in part explain the anti-inflammatory 
effect of CBD, as inverse agonism of CB2 inhibits immune cell migration (Karl, Garner 
& Cheng 2017). CBD may also exert its effect through activation of various other 
targets such as the G-protein coupled receptor 55, transient receptor potential vanilloid 
type 1 and the serotonin 1A receptor (Hartmann et al. 2019), and has been shown to 
inhibit anandamide uptake and hydrolysis, and blunts fatty acid amide hydrolysis, each 
of which help explain the effect of CBD on the ECS as this results in an increase in 
anandamide, allowing CBD to indirectly stimulate cannabinoid receptors (Hartmann 
et al. 2019). CBD has also demonstrated the abilities to protect against neurotoxicity 
via inhibition of uptake of an adenosine transporter (Carrier, Auchampach & Hillard 
2006) and via reduction of glutamate toxicity (Hampson et al. 1998), and increases 
hippocampal neurogenesis in vivo (Wolf et al. 2010). 
 It has been observed that cannabinoids, including CBD, produce biphasic dose 
response curves in relation to anxiety, feeding behaviour, wakefulness, locomotion, 
exploration and ACh release, among other effects. Evidence suggests that rather than 
producing dose-dependent responses, relative high and low dosages of a cannabinoid 
can i) produce the same effect, ii) produce greater effects than medium dosages, or 
vice versa, or iii) have the opposite effect of each other (Rey et al. 2012; Tzavara, 
Wade & Nomikos 2003). For example, preclinical studies have demonstrated that 
CBD produces inverted U-shaped dose-response curves in numerous strains of rats, 
mice and zebrafish in paradigms including the elevated plus maze, prepulse inhibition, 
and memory related tasks, as reviewed (Rey et al. 2012; Zuardi et al. 2017). The in 
vivo anxiolytic, anti-inflammatory action and post-ischemia neuroprotection of CBD 
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has also been demonstrated to have bell-shaped dose-dependency. In human 
volunteers with insomnia, relatively high doses of CBD increases sleep duration, while 
lower doses of CBD increase alertness. CBD also produces biphasic dose responses in 
the suppression of lithium induced vomiting (Zuardi 2008), and the bell-shaped dose-
dependency of CBD’s anxiolytic effect in vivo has been replicated in human studies 
of anxiety in public speaking (Zuardi et al. 2017). It has been suggested that the 
biphasic nature of cannabinoids is related to distinct sub-populations of cannabinoid 
receptors. For example, low doses of the WIN55,212-2 induces a transient stimulation 
of hippocampal ACh efflux in vivo, while a high dose results in a prolonged inhibition 
of ACh efflux. There is evidence that the difference in effects of the synthetic 
cannabinoid was due to a differential sensitivity of distinct subpopulations of CB1 that 
are linked to differing neurotransmitter systems that have opposing effects on ACh 
release (Tzavara, Wade & Nomikos 2003). Furthermore, another study demonstrated 
that a low dosage of CB1 agonist CP 55,940 has anxiolytic properties while a high dose 
has anxiogenic properties. The authors of this study also suggested that the biphasic 
effect on anxiety was due to distinct subpopulations of CB1 that had differing 
sensitivities and were linked to either glutamatergic terminals or GABAergic terminals 
(Rey et al. 2012). Thus, since CBD, as other cannabinoids, exhibits bell-shaped dose 
response curves, it is pivotal to investigate a range of dosages to determine the window 
of therapeutic effectiveness of the drug. 
1.3.3 Evidence for CBD as a therapeutic of AD 
 Various properties of CBD are relevant in the fight against numerous pathological 
symptoms of AD, including the properties of neuroprotection, anti-inflammation and 
antioxidant effects. As such, CBD has shown potential as a therapeutic for AD in 
preclinical studies. Numerous in vitro studies utilising rat PC12 neuronal cells 
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stimulated with Aβ have shown that CBD acts against Aβ-induced toxicity in various 
ways. For example, CBD is able to inhibit tau hyperphosphorylation in a dose-
dependent manner in these cells, and is associated with a reduction in the 
phosphorylated glycogen synthase kinase 3-β, which is responsible for NFT formation 
in AD (Esposito et al. 2006a). Similarly, other studies show that CBD increases cell 
survival and reduces Aβ-induced lipid peroxidation, ROS production (Iuvone et al. 
2004), and attenuates NO production via inhibition of phosphorylated p38 mitogen-
activated protein kinase and transcription factor nuclear factor-κB (Esposito et al. 
2006b). CBD has also demonstrated the ability to counteract the elevation of APP 
expression in transfected human neuroblastoma cells by inducing ubiquitination of 
APP through activation of peroxisome proliferator-activated receptor-γ (PPARγ), 
which is paralleled by a reduction of Aβ peptide expression and increased cell survival 
(Scuderi, Steardo & Esposito 2014). 
 CBD has also shown potential in vivo as a therapeutic for AD. In a pharmacological 
mouse model of AD-related neuroinflammation generated by hippocampal injection 
of Aβ (of lengths one to 42 amino acids), the anti-inflammatory properties of CBD 
were shown to attenuate Aβ-evoked neuroinflammation in a dose dependant manner 
(Esposito et al. 2007b). In a later study using a rat model this effect was identified to 
be mediated via PPARγ (Esposito et al. 2011)), which has been shown to be elevated 
in AD patients (de la Monte & Wands 2006). CBD treatment is also able to prevent an 
Aβ-induced learning deficit of a pharmacological mouse model of AD in the MWM 
(Martín-Moreno et al. 2011). Important for this Masters of Research study is the 
finding that a moderate dosage of CBD, 20 mg/kg bodyweight, has been shown to 
reverse social recognition and novel objection recognition deficits in 6-month-old 
APPxPS1 mice when delivered chronically post-onset of disease-relevant symptoms 
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(Cheng et al. 2014a). This dosage also prevented the development of a social 
recognition deficit in the APPxPS1 model when delivered for 8 months prior to the 
onset of disease symptoms (Cheng et al. 2014c). Similarly, botanical extracts of CBD-
rich cannabis given to APPxPS1 mice at a dosage of 0.75 mg/kg of CBD were found 
to increase the recognition index of mice in the two-object recognition test when 
chronically administered during the early symptomatic stage of AD (Aso, Andrés-
Benito & Ferrer 2016).  
 
1.4 Aims 
1.4.1 Rationale and hypothesis 
 There is currently no cure for AD. Without a significant medical breakthrough, it 
is expected that AD and dementia will cost Australia upwards of $1 trillion by 2056 
and will have significant global impacts also. Development of an effective therapeutic 
agent is urgent and will benefit not only patients but also their families, caregivers, 
and health systems. The current project contributes to a field of research seeking a 
treatment for AD through a preclinical investigation of the therapeutic potential of low 
dose CBD in an animal model relevant for AD, and may guide the development of 
human clinical trials (e.g. in advising drug dose, route of administration, primary 
treatment measures, potential side effects etc.), and may eventually lead towards an 
approved drug for the disease. Further, this project will contribute new insights into 
CBD biology and function for the field of behavioural neuroscience, with the findings 
more specifically adding knowledge about the effects of CBD in the APPxPS1 mouse 
model of AD and the effects of chronic CBD administration in an ageing organism. 
Therefore, in endeavouring to determine the efficacy of CBD as a treatment for 
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dementia, the current project will contribute to the preclinical research effort necessary 
to move toward approval of a treatment for AD to reduce the burden of this disease. 
 There is preclinical evidence that 20 mg/kg body weight CBD is able to reverse 
and prevent signs of AD in the APPxPS1 model, yet a low dosage of 5 mg/kg body 
weight CBD is yet to be studied in the APPxPS1 model. As CBD shows biphasic 
properties, it is hypothesized that chronic treatment of 5 mg/kg body weight might 
show a similar capability to reverse cognitive impairments in the APPxPS1 mouse 
model as did 20 mg/kg body weight CBD, rather than exhibiting dose dependent 
effects. Furthermore, due to the biphasic dose response curve of CBD, there is the 
potential that the chosen low dosage of CBD may have the opposite effect to that of 
20 mg/kg bodyweight CBD, and therefore is necessary to investigate this low dosage. 
It is important to investigate the potential of CBD at a range of dosages, with a low 
dosage of CBD having clinical importance regarding potential minimization of the 
cost of therapy, if CBD were considered as a therapeutic. 
1.4.2 Major aim 
 To determine if a chronic administration regime of 5 mg/kg bodyweight CBD can 
reverse cognitive and motor impairments in the female APPxPS1 transgenic mouse 
model of AD at 12 months of age.   
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Chapter 2: Materials and Methods 
2.1 Animals 
12-month-old female double transgenic APPSwe/PS1ΔE9 (APPxPS1) mice were 
used in this study to model AD, specifically FAD. This model was chosen as APPxPS1 
mice replicate the most relevant features of AD, including cognitive deficits and 
pathological features such as Aβ deposition and oxidative stress damage (Aso et al. 
2015). Female mice were chosen due to availability and also as female APPxPS1 mice 
display higher levels of soluble Aβ40 and Aβ42 compared to males as mentioned 
previously. At 12 months of age the mice are considered to be in an advanced stages 
of the symptomatic phase of AD (Aso, Andrés-Benito & Ferrer 2016). This model 
bears the Swedish mutation of the chimeric mouse/human APP, and the exon-9-
deleted PS1 (PS1ΔE9) mutation on a mixed C57BL/6JxC3H/HeJ background 
(Borchelt et al. 1997; Jankowsky et al. 2004b), as previously mentioned. Female 
APPxPS1 mice (n = 22) and their non-transgenic wild type-like littermates (WT: n = 
28) were 361 ± 8 days old at the onset of the study, with a total of three cohorts of 
mice being used. Mice were bred at Australian BioResources (ABR: Moss Vale, NSW 
Australia) where they were grouped housed in individually ventilated cages (Type 
Mouse Version 1: Airlaw, Smithfield, Australia) under a 12/12 h light/dark cycle with 
a dawn/dusk simulation. Mice were transported to the Western Sydney University 
animal facility (School of Medicine, Campbelltown, Australia) once they had reached 
adulthood where littermates were group housed (2-4 mice per cage). Two weeks prior 
to the start of any experiments, cages containing four mice were separated, ensuring 
group housing of 2-3 mice per cage for the duration of the experimental period. Mice 
were housed in high temperature polysulfone filter top cages (1284L: Tecniplast, 
Rydalmere Australia) and provided with food (Rat & Mouse Pellets: Gordon’s 
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Specialty Stockfeeds Pty Ltd., NSW, Australia) and water ab libitum unless otherwise 
described. Corn-cob bedding (PuraCob premium: Able Scientific, Perth, Australia) as 
well as crinkle paper (Crink-l’Nest, Kraft) and tissue for nesting were used but no 
enriching structures. Cages were changed fortnightly. Standard laboratory conditions 
applied with a 12/12 h light/dark cycle (light phase beginning 0900 with white light at 
an illumination of 124 lux, and dark phase beginning 2100 with red light at an 
illumination of less than 2 lux). Temperature and relative humidity were automatically 
controlled between 20-22 °C and 40-60%, respectively. All procedures were approved 
by the Western Sydney University Animal Care and Ethics Committee (#A12905) and 
complied with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes. 
 
2.2 Drug preparation and administration 
 A preparation of powdered cannabidiol (CAS: 13956-29-1; THC Pharma GmbH, 
Frankfurt/Main, Germany) dissolved to a concentration of 0.5 mg/mL in equal parts 
of Tween80 (Sigma-Aldrich Co., St Louis, USA) and 100% ethanol, and diluted in 
0.9% saline, to a ratio by volume of 1:1:18 ethanol:Tween80:saline was used to 
prepare the CBD treatment solution. A similar solution without the addition of 
powdered cannabidiol (1:1:18 ethanol:Tween80:saline) was used as the vehicle.  
 CBD treatment and vehicle preparations were made up weekly. Firstly, all falcon 
tubes for storage and preparation of the CBD treatment (but not vehicle) were 
siliconized using a solution of a chlorinated organopolysiloxane in heptane 
(Sigmacote; Sigma-Aldrich Co., St Louis, USA). A thin layer of Sigmacote was coated 
onto the inner surface of the falcon tube and allowed to dry to prevent surface 
adsorption of CBD to the plastic. Then, an appropriate weight of powdered CBD was 
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measured using a fine precision balance and dissolved in the appropriate volume of 
the chosen solvent, 100% ethanol. This was vortexed in the siliconised falcon tube for 
approximately 20 s until fully dissolved. An appropriate volume of the surfactant 
Tween80 was added to the solution, which was then vortexed for another 20 s. Finally, 
0.9% saline was added to the solution to a final ratio by volume of 1:1:18 
ethanol:Tween80:saline. This was vortexed for 20 s until completely emulsified.  
 Both ethanol and Tween80 were required to dissolve and facilitate the 
emulsification of CBD in saline, as the hydrophobic properties of CBD mean that it 
does not readily dissolve in saline alone. While 10% ethanol and 10% Tween80 have 
been used as drug vehicles in previous CBD studies, this study chose to limit the 
negative effects that these reagents potentially have on mice by choosing a lower 
percentage of ethanol and Tween80 in the final stock preparations, based on previous 
studies that have had success using the stock volume ratio of 5% ethanol and 5% 
Tween80 (Cheng et al. 2014a). Consideration of the final amount of solvent in the 
vehicle preparation is important considering that ethanol and Tween80 may be toxic 
and can cause altered behavioural effects in mice, such as increased or decreased 
locomotor activity (Castro et al. 1995), when used as drug vehicles at high (16-32%) 
percentages. However, it has been shown that a lower percentage of 5% 
ethanol/Tween80 does not alter locomotor activity (though a combination of the two 
may; Castro et al. (1995)).  
 Half of the weekly CBD batch was refrigerated at 4 °C and used immediately for 
four days, while the other half was frozen at -18 °C for up to three days and defrosted 
and refrigerated for use over the next three days. CBD storage vessels were covered in 
aluminium foil to prevent light exposure to the solution to ensure the CBD remained 
stable, as CBD, like other cannabinoids, is light sensitive and should be stored in 
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darkness (Fairbairn, Liebmann & Rowan 1976). Enough vehicle was prepared to last 
seven days and stored at 4 °C.  
 Mice were quasi-randomly assigned to either treatment or control groups, and it 
was ensured that treatment assignment was counterbalanced across genotype and 
within cages for each cohort. Four experimental groups were set up with the number 
of animals in each group as follows: WT treated with vehicle (WT-VEH), n = 15; WT 
treated with CBD (WT-CBD), n = 13; APPxPS1 treated with vehicle (APPxPS1-
VEH), n = 10; and APPxPS1 mice treated with CBD (APPxPS1-CBD), n = 12. At 
approximately 12 months of age, mice were treated daily with CBD or vehicle for 
three weeks prior to the start of the experiments and daily treatment continued 
throughout the behavioural assessment. The prepared CBD or vehicle solutions were 
administered by intraperitoneal (i.p.) injection at an injection volume of 10 mL/kg 
body weight, utilising a CBD dosage of 5 mg/kg body weight. The route of 
administration was chosen to be via i.p. injections, rather than other modes of 
administration such as oral or intravenous routes, due to the 100% bioavailability of 
this route and the chronic nature of the study (Machholz et al. 2012). Furthermore, i.p. 
injections are more established and in line with other studies investigating the potential 
of chronic administration of CBD as a therapeutic in APPxPS1 mice (Cheng et al. 
2014a). Treatment was always administered in the afternoon to avoid acute effects of 
the injections modifying the behavioural performance of the mice during the 
experimental test period. The site of injection was alternated daily between left and 
right lower abdomen. Body weight was monitored weekly.  
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2.3 Behavioural test battery 
 Mice performed a battery of behavioural paradigms described below to assess 
anxiety, motor function, cognition, and sensorimotor gating. All of these behavioural 
domains have been found to be affected in dementia or AD-relevant mouse models. In 
line with previous studies conducted in our laboratory (Cheng et al. 2014a), all 
experiments were performed during the first 5 h of the light phase to reduce the effects 
of the circadian rhythm on mice performance (i.e. to avoid the less active period of the 
light phase; Grech et al. (2019)), and a 48 h inter-test interval applied for all 
behavioural testing to minimise the effect of repeated testing and to allow mice to rest 
between tests (with the exception of low-impact motor function tests, which were 
performed over three consecutive days). On the day of testing, mice were habituated 
to the test room for 30-60 min prior to testing. Mice were euthanised and tissue 
collected following assessment (further discussed in section 2.4). For a diagrammatic 
view of the study design, please see Figure 3. For an overview of test order and test 
age, please see Table 1.  
 
 
Example of the days on which behavioural testing was conducted for cohort 1 (cohort 
2 and 3 differed slightly). Abbreviation: Australian BioResources (ABR).   
Figure 3: Outline of the study design. 
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Table 1: Test biography. 
Test order and test age [in days, on the first day of each test] of non-transgenic wild 
type-like (WT) control and double transgenic APPSwe/PS1ΔE9 (APPxPS1) female 
mice treated with either vehicle (VEH) or cannabidiol (CBD). Ages [d] are presented 
as mean ± standard error of means (SEM). Abbreviation: Novel object recognition task 
(NORT). No significant differences between days of test. 
 
2.3.1 Light dark (LD)  
 Mice have a natural tendency to explore novel environments while also showing 
aversion to brightly illuminated and exposed areas. Thus, anxiety-related behaviour 
(Crawley 1985) can be assessed by placing mice into the light dark test (LD). In the 
LD, mice are placed into a box that is divided into an enclosed dark zone, which mice 
show a preference for (Crawley 1985), and an exposed and illuminated light zone, 
which mice are inclined to explore but also apprehensive of (that is, they show state 
(spatio-temporal) anxiety; Ramos (2008)). The level at which a mouse explores the 
light zone in comparison to the dark zone is indicative of their level of anxiety, with 
more exploration of the light zone suggestive of reduced anxiety. The behaviours of 
mice in the LD can also be used to assess general activity, for example exploratory 
 
  WT-VEH APPxPS1-VEH WT-CBD APPxPS1-CBD 
Start of CBD treatment 361 ± 2 357 ± 2 363 ± 2 360 ± 2 
Light Dark 382 ± 2 378 ± 2 384 ± 2 381 ± 2 
Pole Test 384 ± 2 380 ± 2 386 ± 2 383 ± 2 
Accelerod 384 ± 2 380 ± 2 386 ± 2 383 ± 2 
NORT 389 ± 2 385 ± 2 391 ± 2 388 ± 2 
Cheeseboard 392 ± 2 388 ± 2 394 ± 2 391 ± 2 
Prepulse Inhibition 406 ± 2 404 ± 2 408 ± 2 405 ± 2 
Tissue Collection 409 ± 2 407 ± 2 411 ± 2 408 ± 2 
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rearing and distance travelled. Thus, the LD test not only tests for state anxiety but 
also assesses exploratory and locomotive behaviours.  
An assessment of anxiety, exploration and locomotion was necessary for this 
study. Cannabinoids have been shown to instigate biphasic anxiety responses (Rey et 
al. 2012), and both patients with AD and the APPxPS1 mouse model of AD show 
changes in anxiety (Lalonde, Kim & Fukuchi 2004) and locomotion (Alzheimer’s 
Association 2018; Cheng et al. 2014b), necessitating the need to investigate these 
factors. Importantly, stress, anxiety and emotion can impact upon cognition (Brinks et 
al. 2007; Harrison, Hosseini & McDonald 2009), so it is essential to examine the 
anxiety phenotype of mice in the LD to consider its impact on other cognitive tests.  
The apparatus (Figure 4) had a total test area of 43.2 cm x 43.2 cm and consisted 
of two equally sized zones: a black and covered (dark: illumination <20 lux) zone, and 
a white and uncovered (light: illumination >200 lux) zone. This was achieved by 
placing a black infrared transmitting plastic dark box insert (model ENV-516: MED 
Associates Inc., St Albans, VT, USA) into the rear half of an infrared photobeam 
controlled open field test chamber (model ENV-515: MED Associates Inc., St Albans, 
VT, USA). An opening in the centre of the dark box insert allowed passage between 
the two zones. After a 1 h habituation to the test room, mice were placed into the dark 
zone and allowed to explore the entire apparatus for 10 min. 80% ethanol was used to 
clean the apparatus between mice. Total distance travelled in the dark zone and total 
distance travelled over time were used as indicators of locomotion. Exploration was 
shown by the frequency of rearing (vertical activity). Percentage time spent and 
percentage distance travelled in the dark zone were calculated to identify anxiety-
related behaviours.  
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Figure 4: Light dark test apparatus. 
Mice were placed into the dark zone of the apparatus at the beginning of the test 
through the hinged lid of the dark box insert, and allowed to explore for 10 min.  
2.3.2 Pole test 
Motor function can become dysfunctional in some AD patients, and the APPxPS1 
model has previously shown motor deficits at 6 months of age (Kuwabara et al. 2014), 
but not in other studies testing at 7 months of age (Lalonde, Kim & Fukuchi 2004); 
thus, this study explored the motor function of test mice.  
Non-specific motor function was assessed using the vertical pole test, whereby 
climbing behaviour, which involves multiple aspects of motor function, is measured 
(Brooks & Dunnett 2009). The apparatus for the pole test (Figure 5) was a 50 cm 
aluminium pole of 1 cm diameter wrapped with masking tape for grip and mounted on 
a base platform. After a 30 min habituation to the test room, mice were placed with 
snouts facing upwards on the end of the pole, which was held horizontally at that stage. 
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Once the mice had grip, the pole was turned upright to a vertical position and the mice 
were allowed to turn around and climb down the pole. Performance was measured by 
the time taken to turn around (latency to inversion), the time taken to descend the pole 
once turned around (time to descend), and the total time taken to reach the platform 
from the beginning of the test (latency to reach the platform; cut off time of 60 s). All 
aforementioned behaviours were recorded manually using a stopwatch. It was also 
recorded as to whether the mice wrapped their tails around the pole for balance, 
however this was not analysed (Figure 5). This procedure was repeated a total of three 
times with a 30 min inter-trial interval (ITI) and the apparatus was cleaned with 80% 
ethanol between trials. The average of the three trials was considered for analysis. 
Figure 5: The pole test apparatus. 
Mice were given a maximum of 60 s to climb down the pole to the platform. Tail 
wrapping is evident.   
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2.3.3 Accelerod 
 An accelerating rotarod paradigm was used to measure the motor coordination and 
balance of the test mice (Brooks & Dunnett 2009), which as previously mentioned can 
become impaired in AD and in the APPxPS1 mouse model. The accelerod test was 
conducted over three days, with the first day occurring on the same day as the pole 
test; the pole test was completed first, and following a 1 h ITI, mice began training to 
the accelerod. The apparatus (Rota-rod model ENV 574M; MED Associates Inc, St. 
Albans, VT, USA; Figure 6) is a five-lane Rota-rod treadmill for mice. On the first 
day mice underwent training to the accelerod to ensure mice understand the task before 
getting tested. During the training, mice were placed on the rotating cylinder of the 
apparatus, facing the opposite direction of rotation, which ensured the mice walked to 
stay on the beam. Mice were given three x 2 min training trials with the beam rotating 
at a continuous speed of 12 revolutions per minute (rpm), with an ITI of approximately 
20 min. Mice were replaced on the accelerod if they fell off during training. On the 
second and third day, during the test phase, mice were habituated to the room for 30 
min, and were then placed on the beam, which was set to slowly accelerate from 4 rpm 
to 40 rpm over a 4.5 min period, and ended with a 30 s period at a continuous 40 rpm 
speed. Performance was measured as the time at which mice fall from the cylinder 
(latency to fall), which was automatically detected and recorded by sensors. This 
procedure was repeated twice per day with an ITI of 1 h (four test trials across two 
days). 80% ethanol was used to clean the apparatus between trials. The mean of the 




Figure 6: The accelerod apparatus. 
The Rota-rod treadmill for mice consists of a rotating beam and allows for testing of 
up to five mice at a time. 
 
 
2.3.4 Novel object recognition task (NORT) 
 The innate preference of a mouse for novelty, and their ability to distinguish a 
novel object from a familiar object (Dere, Huston & De Souza Silva 2007) is utilised 
in this test to determine object recognition memory, an aspect of cognition. Cognition, 
and especially recognition, is severely impaired in AD patients and is replicated in the 
APPxPS1 model, and may be able to be rescued by CBD (Cheng et al. 2014a; Cheng 
et al. 2014c). Thus, object recognition memory was assessed in this study.  
 The apparatus for the NORT paradigm was a grey PVC arena (300 mm x 350 mm 
x 350 mm; Figure 7), which mice were habituated to for 10 min one day prior to 
testing. On the test day, 24 h later, mice were habituated to the test room for 30 min. 
The testing was carried out across two trials. In trial 1, the ‘training’ trial, two identical 
objects (each a stack of LEGO blocks) were placed and secured via a reusable adhesive 
(so that mice could not move the objects) in opposite corners of the NORT arena, and 
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mice were placed into one of the remaining empty corners and allowed to explore the 
arena and the objects for 10 min. In trial 2, the ‘testing’ trial, one of the now ‘familiar’ 
objects from trial 1 was replaced with a LEGO Duplo giraffe (the ‘novel’ object). Mice 
were again placed into one of the empty corners and allowed to explore arena and 
objects for 10 min. A 15 min ITI was used and the arena and objects were cleaned with 
80% ethanol between trials to remove any scent cues. The location of the novel object 
(left corner or right corner) was counterbalanced across genotype. Both trials were 
video recorded using AnyMaze tracking software (Stoelting, Wood Dale, USA), and 
the time spent nosing the objects was later manually scored (nosing was determined 
when the animal’s nose was facing the direction of the object and was sniffing at a 
distance of less than 5mm away). The percentage of time spent nosing the novel object 
was calculated [(novel object nosing time) / (novel + familiar object nosing time) × 
100] and used as an indication of object recognition memory, also known as the 
recognition index. One APPxPS1-CBD mouse died prior to NORT testing. Of the 
remaining mice, one WT-VEH mouse and one APPxPS1-CBD mouse were excluded 
from analysis, as these mice did not meet the requirements of the task (a minimum of 
20 s exploration during both trials), as they showed extensive freezing behaviour 
during training and/or testing. This exclusion criterion is in line with previously 
published studies from our lab using NORT (Cheng et al. 2014a). Extensive freezing 




Figure 7: The novel object recognition task (NORT) paradigm; testing trial. 
In the square, grey NORT arena, a stack of LEGO blocks (upper left) was used as the 
‘familiar’ object, while a LEGO Duplo giraffe (lower right) was used as the ‘novel’ 
object in the testing trial. 
 
 
2.3.5 Cheeseboard (CB) 
 Spatial disorientation is a significant symptom of AD patients and is replicated in 
the APPxPS1 model (Cheng et al. 2014b; Reiserer et al. 2007); thus, aspects of spatial 
memory were assessed in this study through the cheeseboard (CB) paradigm. The CB 
was chosen as a less-strenuous dry-land substitute for the MWM to assess spatial 
learning acquisition and spatial reference memory, in line with previous studies in our 
lab (Cheng et al. 2014b). Unlike the MWM, the CB uses positive reinforcement (a 
food reward) and motivates mice to learn through hunger, rather than the motivation 
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of survival to learn to avoid drowning (Grech et al. 2019). This factor makes the CB a 
less-stressful alternative to the MWM. Furthermore, unlike rats, for which the MWM 
was originally designed for, mice are not natural swimmers and can show exhaustion 
in the MWM, as well as floating behaviour, thigmotaxis and hypothermia (Lopez et 
al. 2010); thus, employment of the more ideal CB in this study eliminates these 
factors. 
The apparatus was a circular grey wooden board (110 cm diameter; Figure 8), 
with one side blank, and one side covered by 32 wells, arranged in eight equal 
zones containing four wells each. The board was placed in the test room and 
surrounded by visual external cues that were not changed during testing to enable 
spatial orientation. External cues were large black or white shapes, for example a 
circle, square or plus sign (Figure 5), on contrasting backgrounds placed no more 
than 30 cm from the edge of the board. The illumination of the test room was 
dimmed to 50 lux to ensure mice were not afraid while on the board, which was 75 
cm from the ground.  
Motivation to find the food reward during testing was achieved through a 
food deprivation schedule. Mice were food restricted, beginning in the afternoon of 
the day prior to habituation to the apparatus, to a maximum of 85% of their free-
feeding body weight throughout the entire testing period. One hour following 
completion of the last trial of each daily cheeseboard task, mice were given access to 
food for at least 60 min and up to 120 min if required to guarantee the indicated 
weight loss. Food was provided ad libitum following the final reversal probe. The 
food reward was sweetened condensed milk diluted with water to a ratio of 1:4 
milk:water. Mice were habituated to the food reward immediately following the final 
trial (and prior to feeding for the day while the mice were hungry) on days 1-5 
(during habituation to the board and on training days 1 to 3 while mice were still 
adapting to the food reward). For habituation to the food reward, mice were given a 
capful (~1ml) each of food reward in their home 
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cage. Each day, 1 h after feeding for the day, mice were weighed and then injected 
with CBD or vehicle. 
Figure 8: The cheeseboard paradigm; training trial. 
 A single well (lower right) was baited during training trials on the circular board. Two 
of the many spatial cues can be seen to the left of the apparatus. 
Mice were habituated to the test room for 30 min each day and were tested in 
groups of 6-7. For each group of mice being tested, the filter top lids of the home cages 
were removed and placed under the corresponding cages prior to commencement of 
testing. The wire cage hopper was left on top of the home cage. This was implemented 
to minimise the disruption caused by adjusting the cage lids while retrieving the next 
mouse to be placed on the board. During all trials, mice were placed in the centre of 
the board using a start box, and once the box was removed mice were allowed to freely 
explore the board. All trials were video recorded with AnyMaze tracking software. 
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Mice were habituated to the blank side of the board for the first two days; mice were 
allowed to freely explore the board for 2 min for a total of three trials each day, with 
an ITI of 20 min.  
The remainder of the test was performed on the side of the board containing the 
wells, each containing a bottle cap that was brushed with the food reward to remove 
possibility of odour cues distracting or guiding the mice. Days 3 to 7 consisted of three 
training trials per day (20 min ITI), during which spatial learning acquisition was 
made. During training trials, one cap (~1 ml) of food reward was available on the 
board, and the latency of the mice to find and drink the food reward was recorded with 
a stopwatch. Each trial was a maximum of 2 min; if the mouse hadn’t found the food 
reward within these 2 min, it was gently guided to the well by the experimenter. All 
mice were allowed to drink from the baited well for no longer than 10 s. A total of five 
training days were run (i.e. total of 15 training trials). The position of the baited well 
was limited to the second and third row of wells (the inner and outer row of wells 
closest and furthest from the centre, respectively, were excluded to minimise the 
difference in distance that mice had to travel to the food reward; Figure 9). The baited 
well was the same for each day and each trial per mouse so that they would learn the 
location of the well, but a different well was baited between mice, and counterbalanced 
for genotype and treatment. The average latency of mice to find the reward for all three 
trials per day was analysed as a general indication of learning, while the first trial per 
day was analysed to assess long-term reference memory (retention of ≥ 24 h), and the 
average of trials 2 and 3 (each ~ 20 min following the previous trial) was analysed to 
assess intermediate-term memory (retention falling between that of short-term 
memory (2 min) and of long-term memory (24 h; Taglialatela et al. (2009)), i.e. ~20 
min in this test, and spanning up to several hours). Mean speed was also assessed.
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Figure 9: Cheeseboard schematic. 
The cheeseboard has a circular centre zone and eight wedge shaped target zones, each 
containing four wells and extending to include the area proximal to the wells. One well 
is baited during training (coloured red in zone 8), but not during the probe trial, 
and the opposite well is baited during reversal training (coloured blue in zone 4). The 
inner and outer wells are never baited (indicated with a red cross in zone 3).  
The CB probe trial for spatial memory was performed on day 8. For the probe, no 
food reward was placed on the board, but all caps were lightly brushed with the food 
reward. Mice were placed on the board and given 2 min to explore the board. The 
percentage of duration spent in the target zone for the full 2 min, and also for the first 
and second 30 s was calculated (to account for potential differences in behavioural 
flexibility rather than spatial memory; Grech et al. (2019)) post experiment using data 
from AnyMaze, and  used as an indication of  spatial memory.  The  target  zone is        
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defined as the one zone out of the eight zones that during training held the baited 
well; the target zone therefore constituted 12.5% of the circular board and contained 
one row of four wells and the area adjacent to these wells (Figure 9). If mice spent 
significantly greater than 12.5% of their time in the target zone (greater than 
chance), then it was concluded that the mouse had developed a preference for this 
zone and therefore exhibited intact spatial memory. Increased time spent in the target 
zone in the first 30 s was indicative of intact retrieval memory, demonstrating that 
mice recall the position of the food reward from the day prior. Increased time in the 
target zone over next 30 s was indicative of perseverative behaviour, i.e. 
persistence to find the food reward in the target zone, while decreased time in the target 
zone over the second 30 s might be indicative of cognitive flexibility in adaptation to 
the lack of food reward (Grech et al. 2019). One APPxPS1-CBD mouse was excluded 
from probe analysis as it froze for 80 s (3x greater than any other mouse that showed 
some freezing behaviour).  
A CB reversal (rCB) test was also completed; training began on day 9, 24 h post 
completion of the probe trial. For this, the opposite well on the board that was used in 
the initial training trials was baited (Figure 9). Mice were given four days of reversal 
training. Then on day 13, a reversal probe trial was carried out. The test procedures for 
initial training and probe trial and the reversal training and probe trial were identical. 
One APPxPS1-VEH and one APPxPS1-CBD mouse were included in the analysis of 
the whole 2 min of the test, but were excluded from analysis of the first and second 30 
s of the reversal probe due to a technical issue that meant data for the whole 2 min was 
not able to be accurately split into 30 s bins for these two mice. 
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2.3.6 Prepulse inhibition (PPI)  
 There is recent evidence of reduced prepulse inhibition (PPI) in early stages of AD 
(Ueki et al. 2006), and in AD mouse models (Wang et al. 2012); thus this test was used 
to assess the acoustic startle response (ASR) and sensorimotor gating (also known as 
PPI). ASR is measured as the startle amplitude (arbitrary units) of an organism in 
response to an acoustic startling stimulus (in this test, a loud startle pulse of 100 or 120 
decibels (dB)). The startle response can also be measured using visual or tactile 
stimuli, for example a flash of light, or puff of air to the eye (Swerdlow et al. 2001). 
Sensorimotor gating or PPI is a neurological mechanism that inhibits the processing 
of extraneous information, and in this test is the occurrence by which a weaker, non-
startling prestimulus presented prior to a subsequent, stronger startling stimulus 
attenuates the startle response (Wang et al. 2012). In this test, the prestimulus was an 
acoustic prepulse of 74, 82 or 86 dB.  
 The apparatus consisted of a Plexiglas mouse enclosure (Figure 10) within a startle 
chamber (SR-Lab, San Diego Instruments, San Diego, USA), to which mice were 
habituated for 10 min twice per day (1 h ITI) over two consecutive days prior to the 
test day (total of four habituation trials of 10 min each on day 1 and 2). A consistent 
background noise of 70 dB was presented to mice in the enclosure for all habituation 
trials. On day 3, mice were returned to the apparatus for the PPI test. The test session 
was 35 min long and firstly consisted of a 5 min acclimation period to 70 dB 
background noise, followed by 97 trials presented in a pseudorandom order. The trials 
consisted of; 5 x 70 dB trials (no stimulus, background noise), 5 x 100 dB trials and 
15 (3 blocks of 5 presented at the beginning, middle and end of the test) x 120 dB trials 
to test for ASR; and 72 trials of a prepulse (74, 82 or 86 dB) presented 32, 64, 128, or 
256 ms (variable inter-stimulus interval; ISI) prior to a startle pulse of 120 dB to test 
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for PPI. Each prepulse x ISI combination was randomly presented six times, and the 
interval between each trial (ITI) varied randomly between 10 – 20 s. The startle 
responses to each trial were detected by the accelerometer as the average mean 
amplitude detected. ASR was calculated as the mean amplitude to all startle trials. 
ASR habituation was analysed by comparing the 5 blocks of 120 dB startle pulses at 
the beginning, the middle and the end of the PPI. Percentage PPI (%PPI) was 
calculated as [(mean startle response (120 dB) – PPI response)/mean startle response 




Figure 10: The prepulse inhibition mouse enclosure. 
The reflective response of the mice to the startle pulse is recorded by an accelerometer 
attached underneath the enclosure.  
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2.4 Tissue collection 
 Following completion of behavioural testing, the test mice were euthanised and 
their brain tissue collected for future molecular analysis (for time reasons this was not 
possible to be carried out as part of this Master of Research Project). Two key 
pathological signs of AD are the presence of extracellular deposits of Aβ and 
intracellular NFT of hyperphosphorylated tau in brains of both human patients and 
APPxPS1 transgenic mice (Aso, Andrés-Benito & Ferrer 2016). Thus, brain tissue was 
collected for future analysis of these proteins to determine the effect of CBD on AD-
relevant brain pathology in this mouse model, to accompany the already completed 
behavioural analysis. It is expected that future molecular analysis will involve the 
quantification of AD-relevant proteins including soluble and insoluble Aβ40 and Aβ42 
through an enzyme-linked immunosorbent assay (ELISA) in the PFC, hippocampus 
and cerebellum of mice as published previously (Cheng et al. 2014c). Future analysis 
could also investigate levels of ionized calcium binding adaptor molecule 1 (IBA-1) 
to determine microglial activity. We could also investigate the cytokines TNF-α and 
interleukin 1 beta (IL-1β) to determine levels of neuroinflammation. 
2.4.1 Reagent preparation 
 2L of 1x phosphate buffered saline (PBS) was prepared by dissolving 16 g sodium 
chloride (NaCl), 0.4 g potassium chloride (KCl), 2.88 g sodium phosphate dibasic 
(Na2HPO4) and 0.48 g potassium phosphate monobasic (KH2PO4) in water, which was 
then refrigerated at 4 °C. The final concentration of 1x PBS was 137 mM NaCl, 2.7 
mM KCl, 10mM Na2HPO4 and 1.8 mM. KH2PO4.  
 200 mL 4% (w/v) paraformaldehyde (PFA) was prepared in a ventilated fume hood 
by adding 8 g powdered PFA to 200 mL 1x PBS that had been heated to 60 °C. The 
PFA solution was maintained at 60 °C on a hotplate and mixed using a magnetic stirrer 
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for approximately 1 h or until clear. Once dissolved, PFA was filtered through filter 
paper and stored at 4 °C in a spark proof fridge.  
 100 mL of 30% (w/v) sucrose was made by dissolving 30 g white sugar in 100 mL 
PBS and was stored at 4 °C. Fresh reagents were made for each cohort of mice one 
day prior to sacrifice. All chemicals used in the preparation of reagents are from 
Sigma-Aldrich Co., St Louis, USA. 
2.4.2 Anaesthesia and euthanasia  
 Mice were individually anaesthetised in an anaesthesia chamber containing 
isoflurane (Veterinary Companies of Australia, Sydney, Australia) soaked cotton wool 
placed underneath a metal plate that separated the paws of the mice from the liquid 
anaesthetic. Lack of reflexes including the eye blink, toe pinch and tail pinch 
determined adequate anaesthesia. Anesthetised mice were then transcardially perfused 
by an experienced experimenter with 1x PBS to remove blood and collect tissue and 
then decapitated for euthanasia.  
 Briefly, the anaesthetised mouse was laid out flat on its back on a dissecting board. 
The snout of the mouse was placed into a nose cone containing a cotton ball soaked in 
isoflurane to maintain anaesthesia, and the limbs were secured with tape. The heart 
was exposed using cuts along the sides of the torso, the abdomen and then the thorax 
of the animal, with the diaphragm cut within 20 s of the procedure. A 23G x 3/4" 
butterfly needle was inserted into the left ventricle to puncture the heart. The butterfly 
needle was connected to a tube that connected to the perfusion pump, and which had 
previously been flushed with 1x PBS to ensure that there were no trapped air bubbles. 
Next, the right atrium was cut, and the perfusion pump activated at a flow rate of a 
maximum of 10 ml/min. The circulatory system was flushed until the exit fluid was 
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clear and the liver, kidneys and other organs were blanched (within 2 min). The mouse 
was then decapitated using scissors.  
2.4.3 Sample collection  
 Tail tips were collected from the euthanised mice and snap frozen in liquid nitrogen 
and stored at -80 °C for future genotype confirmation analysis, which has not yet been 
performed. Brains were quickly removed and rinsed in ice-cold PBS before being 
sagittally divided on ice. The left hemisphere was dissected, with the olfactory bulb, 
cerebellum, PFC and hippocampal samples being removed and snap frozen in liquid 
nitrogen before being moved to -80 °C for long-term storage and future molecular 
analysis. The right hemisphere was fixed in 4% PFA and refrigerated at 4 °C for 24 h, 
before being washed in 1x PBS and then placed into a 5ml tube of 30% sucrose. Once 
the right hemisphere had sunk to the bottom of the tube (approximately 24 h), 
indicating that brains had absorbed the sucrose to signify adequate cryoprotection, it 
was removed from the sucrose and slowly frozen (to prevent cracking); the hemisphere 
was patted dry of sucrose, and held over liquid nitrogen in a plastic cap until frozen, 
before being stored at −80 °C for future analysis. 
 
2.5 Statistical analysis 
 Prior to analysis of behavioural parameters, three-way analysis of variance 
(ANOVA) was used to ensure no ‘cohort’ effects on ‘genotype’ or ‘treatment’ for the 
main parameter of each test. As no ‘cohort’ effects were found (data not shown) all 
further analysis considered the three cohorts as one. Analysis of measured parameters 
was performed using two-way ANOVA to determine main effects of between-subject 
factors ‘genotype’, ‘treatment’ and ‘genotype’ by ‘treatment’ interactions. Three-way 
repeated measures (RM) ANOVA was also used to investigate repeated measures 
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effects of within-subject factors of ‘time’ (LD), ‘object’ (NORT), ‘time’ (CB), and 
‘startle pulse intensity,’ ‘startle block’ and ‘prepulse intensity’ (all PPI). One sample 
t-tests were also used for LD, NORT and CB probe to determine whether a specific 
behaviour was above chance levels (i.e. 50% for LD and NORT – 12.5% for CB). 
Significant differences were determined when p < .05. F-values and degrees of 
freedom are presented for ANOVA and significant effects of ‘genotype’ are shown in 
figures and tables by ‘*’ (*p < .05, **p < .01, and ***p < .001), and significant effects 
of ‘treatment’ are shown by ‘#’ (#p < .05). Significant RM results are indicated by ‘^’ 
(^p < .05, ^^p < .01, and ^^^p < .001). Significant t-test results are also shown by ‘+’ 
(+p < .05, ++p < .01, and +++p < .001). Trends were reported when .05 < p < .09, and 
all other non-significant data were reported as p > .05. Data are shown as means ± 
standard error of means (SEM). All statistical analyses were conducted using SPSS 
25.0 for Mac. 
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Chapter 3: Results 
3.1 Locomotion and exploration 
APPxPS1 mice displayed increased total distance travelled in the LD test [two-
way ANOVA for ‘genotype’: F(1,46) = 9.2, p = .004] and this increase in locomotion 
was not affected by treatment (i.e. no ‘genotype’ by ‘treatment’ interaction, p > .05; 
Table 2 and Figure 11A). Importantly, this hyper-locomotive phenotype of APPxPS1 
females was replicated when analysing distance travelled in the dark zone, which is 
the locomotion measure of the LD paradigm least affected by anxiety [F(1,46) = 16.3, 
p < .001; Table 2 and Figure 11B]. All mice habituated to the LD arena across time as 
indicated by reduced locomotion across 5-min bins in the whole LD arena [RM 
ANOVA for ‘time’: F(1,46) = 117.8, p < .001; Figure 11A] as well as the dark zone 
only [‘time’: F(1,46) = 34.5, p < .001; Figure 11B]. Neither genotype nor CBD 
treatment impacted on the habituation of the locomotor response (no interaction effects 
of ‘genotype’ or ‘treatment’ with ‘time’: all p’s > .05). 
Table 2: Locomotion in the light dark test. 
Data shown for non-transgenic wild type-like (WT) control and double transgenic 
APPSwe/PS1ΔE9 (APPxPS1) female mice treated chronically with either vehicle 
(VEH) or cannabidiol (CBD). Data are presented as mean ± SEM. Main ‘genotype’ 
effects across treatment conditions are presented as ‘*’ (**p < .01 and ***p < .001). 
WT-VEH APPxPS1-VEH WT-CBD APPxPS1-CBD 
Total distance 
[m]** 
32.5 ± 1.6 40.0 ± 2.9 32.4 ± 1.5 38.7 ± 3.1 
Dark zone 
distance [m]*** 
17.0 ± 1.1 21.4 ± 1.8 17.1 ± .9 23.4 ± 1.5 
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Figure 11A-B: Habituation in the light dark test. 
A) Habituation to the entire apparatus and B) to the dark zone, as distance travelled
[m] over time. Data for non-transgenic wild type-like (WT) control and double
transgenic APPSwe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle
(VEH) or cannabidiol (CBD) are shown as means + SEM. Significant main effects of
‘genotype’ are indicated by ‘*’ (**p < .01 and ***p < .001), and repeated measures
effects of ‘time’ by ‘^’ (^^^p < .001).
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Exploration was determined by the number of rearing events in the LD arena. 
Interestingly, mice treated with CBD exhibited an increased frequency of exploratory 
rearing in the dark zone of the LD compared to vehicle-treated mice [two-way 
ANOVA for ‘treatment’: F(1,46) = 5.5, p = .02; Figure 12], and this was not affected 
by genotype (no ‘genotype’ by ‘treatment’ interaction and no main effect of 
‘genotype’, all p’s > .05), This CBD-induced increase in rearing activity was absent 
in the light zone and the full LD arena and was also not affected by ‘genotype’ (all p’s 
> .05 for; data not shown).
Figure 12: Exploration in the light dark test. 
Rearing frequency [n] in the dark zone. Data for non-transgenic wild type-like (WT) 
control and double transgenic APPSwe/PS1ΔE9 (APPxPS1) female mice treated with 
either vehicle (VEH) or cannabidiol (CBD) are shown as means + SEM. Significant 
main effects of ‘treatment’ are indicated by ‘#’ (#p < .05). 
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3.2 Anxiety 
Two-way ANOVA indicated that there was an overall effect of ‘genotype’ for the 
anxiety-related parameters of the LD test. In particular, APPxPS1 mice spent a 
significantly higher percentage of the test time in the traditionally less aversive dark 
zone compared to WT females [F(1,46) = 4.9, p = .03; Figure 13A] and they also 
tended to travel more in the dark zone than their control littermates [i.e. percentage 
distance travelled in the dark zone: F(1,46) = 3.6, p = .06; Figure 13B]. However, a 
comprehensive analysis of the anxiety parameters in the LD test revealed that WT 
mice did not show the expected preference for the dark zone. Indeed, one sample t-test 
for the percentage time spent and percentage distance travelled in the dark zone 
indicated that neither WT-VEH, APPxPS1-VEH nor WT-CBD mice demonstrated a 
significant preference for the dark zone above chance levels (50%), i.e. these 
experimental groups spent an equal amount of time (and travelled equally far) in both 
zones of the LD arena [percentage time in dark zone: WT-VEH; t(14) = 1.1, p = .3, 
APPxPS1-VEH; t(9) = 1.0, p = .3, WT-CBD; t(12) = 1.7, p = .1 - percentage distance 
travelled in dark zone: WT-VEH; t(14) = -.6, p = .5, APPxPS1-VEH; t(9) = .2, p = .8, 
WT-CBD; t(12) = -1.3, p = .2; Figure13A-B]. Only APPxPS1 mice chronically treated 
with CBD exhibited a preference for the dark zone [percentage time: t(11) = 3.0, p = 
.01 - percentage distance travelled; t(11) = 4.9, p < .001; Figure13A-B].  
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Figure 13A-B: Anxiety measures in the light dark test. 
A) Percentage of time spent in the dark zone [%] and B) percentage of total distance
travelled in the dark zone [%]. Data for non-transgenic wild type-like (WT) control
and double transgenic APPSwe/PS1ΔE9 (APPxPS1) female mice treated with either
vehicle (VEH) or cannabidiol (CBD) are shown as means + SEM. Significant two-
way ANOVA ‘genotype’ effects are indicated with ‘*’ (*p < .05), and trend for
‘genotype’ effects indicated by ‘p = .06’. Single sample t-test results against chance
levels are indicated by ‘+’ (+p < .05, +++p < .001).
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As WT mice did not show a preference for the dark zone using the automatic 
tracking system and zone settings provided by the manufacturer (shown in Figure 
14A), we also tested LD zone preferences when considering an exclusion zone around 
the dark zone entry area (Figure 14B) to avoid that potential risk-assessment 
behaviours (i.e. stretch-attend postures) had confounded the LD zone preference 
scores. Based on this central exclusion zone, behaviours of mice in the “new dark 
zone” and “new light zone” were used to determine zone preferences. However, 
adding an exclusion zone did not change the original finding, i.e. most experimental 
groups did not show a preference for the dark zone (data not shown); that is, only the 
APPxPS1-CBD experimental group showed a preference for the dark zone using these 
new settings.  
Figure 14A-B: Light dark test zone settings. 
A) The original MED Associates Inc. zone settings used in the analysis of anxiety
(dark zone location; X:0 and Y:17, and light zone location; X:0, Y:8.5. Size of each
dark and light zone; 17 x 8.5 beams, 26.99 x 13.49 cm) and B) the new zone settings
used for the reanalysis of the light dark (LD) test (dark zone location; X:0 and Y:17,
central exclusion zone location; X:0, Y:9.5, and light zone location; X:0, Y:7.5. Size
of each dark and light zone; 17 x 7.5 beams, 26.99 x 11.91 cm. Size of central exclusion
zone; 26.99 x 3.18 cm).
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3.3 Motor function 
The motor abilities of mice in the pole test were not affected by the APPxPS1 
transgenes nor by CBD treatment, i.e. no significant main effects were found for the 
measures inversion time, latency to reach the platform, and the time to descend once 
inverted [all p’s > .05; Table 3]. Similarly, in the accelerod, two-way ANOVA found 
no effects of ‘genotype’ or ‘treatment’ for the average latency to fall from the accelerod 
[all p’s > .05; Figure 15A]. However, a significant effect of ‘genotype’ was found 
when comparing the worst performance of test mice across trials (i.e. the shortest 
latency across the four trials); APPxPS1 mice fell from the accelerod significantly 
earlier than WT mice [F(1,46) = 7.1, p = .01; Figure 15B]. This effect of genotype was 
not affected by CBD (no ‘genotype’ by ‘treatment’ interaction, p > .05). There was no 
genotype difference in the latency of mice to fall from the accelerod when considering 
the best performance (i.e. the longest latency across four trials: p >.05; Figure 15C). 
CBD treatment had no effect on any accelerod performance measures (all p’s > .05). 
Table 3: Motor functions in the pole test. 
Data shown for non-transgenic wild type-like (WT) control and double transgenic 
APPSwe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or 
cannabidiol (CBD). Data are presented as mean ± SEM. 
WT-VEH APPxPS1-VEH WT-CBD APPxPS1-CBD 
Inversion time 
[s] 
13.8 ± 2.9 14.0 ± 3.8 7.6 ± 1.2 10.7 ± 2.5 
Latency to 
platform [s] 
31.6 ± 4.4 32.2 ± 5.2 22.7 ± 1.8 28.7 ± 3.9 
Time to descend 
once inverted [s] 
17.8 ± 2.0 18.2 ± 2.7 15.0 ± 1.3 18.0 ± 2.2 
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Figure 15A-C: Motor performance in the accelerod. 
A) The average latency [s], B) worst performing latency [s] and C) best performing
latency [s] to fall from the accelerod of the four trials. Data for non-transgenic wild
type-like (WT) control and double transgenic APPSwe/PS1ΔE9 (APPxPS1) female
mice treated with either vehicle (VEH) or cannabidiol (CBD) are shown as means +
SEM. Significant ‘genotype’ effects are indicated with ‘*’ (*p < .05).
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3.4 Cognition 
3.4.1 Object recognition memory (NORT) 
In the NORT testing trial, all experimental groups, excluding APPxPS1-VEH 
mice, had a preference for the novel object which was significantly above chance level 
(50%), as indicated by one sample t-tests for the time spent nosing the novel object (as 
a percentage of the total time spent nosing both the novel and familiar objects) [WT-
VEH; t(13) = 4.5, p = .001, APPxPS1-VEH; t(9) = .5, p = .6, WT-CBD; t(12) = 2.8, p 
= .02, APPxPS1-CBD; t(9) = 2.6, p = .03; Figure 16].  
Figure 16: Novel object recognition. 
The percentage of time spent nosing the novel object in the NORT. Data for non-
transgenic wild type-like (WT) control and double transgenic APPSwe/PS1ΔE9 
(APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are 
shown as means + SEM. Significant t-test results are indicated with ‘*’ (*p < .05, **p 
< .01). 
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3.4.2 Spatial memory test – task acquisition and mean speed 
In the CB training trials, all mice demonstrated successful task acquisition as they 
learned the position of the baited well. This was indicated by a reduced latency to find 
the food reward over time, when averaged across the three trials per day [three-way 
RM ANOVA for ‘time’: F(4,180) = 88.6, p < .001; Figure 17A], and also when 
considering intermediate-term memory (average of trials 2 and 3: F(4,180) = 59.3, p < 
.001; Figure 17B). Although APPxPS1 mice took longer per day to find the reward 
(main effect of ‘genotype’ for average of all 3 trials: F(1,45) = 6.8, p = .01 - for average 
of trial 2 and 3: F(1,45) = 11.1, p = .002; Figure 17A-B), their decreasing latency to 
find the food reward across trials and days paralleled that of WT mice, indicating 
learning was similar across genotypes (no interaction of ‘time’ with ‘genotype’, p > 
.05). When looking at the training performance of the mice based on reference memory 
only (i.e. comparing trial 1 of each day only), all mice exhibited a decrease in latency 
to find the food reward over time [‘time’: F(4,180) = 41.6, p < .001; Figure 17C] and 
this was not affected by genotype or CBD treatment (no interactions with ‘time’: all 
p’s > .05). To analyse the APPxPS1 genotype effect on training latencies further, 
analysis of the mean speed of mice across the CB training trials was carried out. 
Indeed, APPxPS1 transgenic mice were slower on the board than their WT littermates, 
regardless of treatment [three-way RM ANOVA for ‘genotype’: F(1,45) = 24.5, p < 
.001; Figure 18A]. There were no effects of ‘treatment’ and no interactions between 
‘genotype’ and ‘treatment’ on the speed during the training trials (all p’s > .05). 
Interestingly, the mean speed of all mice during CB training increased over days 
[three-way RM ANOVA for ‘time’: F(4,180) = 7.8, p < .001; Figure 18A], with no 
interaction of ‘genotype’ or ‘treatment’ between ‘time’ (p’s >.05). 
75 
During reversal training, all mice adapted to the alteration in the food reward 
position and showed decreasing latencies to find the food reward over days [three-way 
RM ANOVA for ‘time’ across three trials: F(3,135) = 47.2, p < .001 - across trials 2 
and 3: F(3,135) = 20.5, p < .001 - across trial 1 only: F(3,135) = 38.9, p < .001]. There 
was no ‘time’ by ‘genotype’ or ‘time’ by ‘treatment’ interactions for any of these 
learning performances (all p’s > .05; Figure 19A-C]. A main effect of ‘genotype’ 
[across three trials: F(1,45) = 17.9, p < .001 - across trials 2 and 3: F(1,45) = 22.3, p < 
.001 - across trial 1 only: F(1,45) = 7.0, p = .007] indicated that APPxPS1 mice took 
generally longer to find the reward than WT mice. Similar to the initial training, when 
analysing the mean speed of mice during the rCB training trials, APPxPS1 mice were 
slower on the board than their WT littermates, regardless of treatment [main effect of 
‘genotype’: F(1,45) = 17.2, p < .001; Figure 18B]. There were no effects of ‘treatment’ 
and no interactions between ‘genotype’ and ‘treatment’ for the speed during the rCB 
training trials (all p’s > .05). Different to the initial training period, the mean speed of 
all mice during rCB training did not increase (p > .05), with the mean speed during 
rCB remaining constant across days.  
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Figure 17A-C: Spatial learning in the cheeseboard (CB). 
Latency [s] to find the food reward during CB training A) averaged across all three 
trials, B) averaged across trials 2 and trial 3, and C) across trial 1. Data for non-
transgenic wild type-like (WT) control and double transgenic APPSwe/PS1ΔE9 
(APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are 
shown as means + SEM. Significant ‘genotype’ effects are indicated by‘*’ (*p < .05, 
and **p < .01) and learning (effect of RM ‘time’) is indicated by ‘^’ (^^^p < .001).  
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Figure 18A-B: Mean speed during cheeseboard (CB) and reversal cheeseboard 
(rCB) training. 
Mean speed [m/s] averaged across all three trials for A) CB training and B) rCB 
training. Data for non-transgenic wild type-like (WT) control and double transgenic 
APPSwe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or 
cannabidiol (CBD) are shown as means + SEM. Significant ‘genotype’ effects are 
indicated by ‘*’ (***p < .001) and effect of RM ‘time’ is indicated by ‘^’ (^^^p < 
.001). 
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Figure 19A-C: Spatial learning in the reversal cheeseboard (rCB). 
Latency [s] to find the food reward during rCB training A) averaged across all three 
trials, B) averaged across trials 2 and trial 3, and C) across trial 1. Data for non-
transgenic wild type-like (WT) control and double transgenic APPSwe/PS1ΔE9 
(APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol (CBD) are 
shown as means + SEM. Significant ‘genotype’ effects are indicated by ‘*’ (**p < .01, 
and ***p < .001) and learning (effect of RM ‘time’) is indicated by ‘^’ (^^^p < .001).  
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3.4.3 Spatial memory, memory retrieval and perseverance 
During the CB probe trial, all mice spent greater than 12.5% of the total 2 min test 
time in the target zone, demonstrating that all mice regardless of ‘genotype’ or 
‘treatment’ successfully recalled the position of the baited well as they showed a 
preference for the target zone greater than chance [one sample t-test: WT-VEH; t(14) 
= 4.4, p = .001, APPxPS1-VEH; t(9) = 4.2, p = .002, WT-CBD; t(12) = 5.5, p < .001, 
APPxPS1-CBD; t(9) = 3.4, p = .007; Figure 20A]. It was observed that some mice did 
not leave the centre zone immediately, and therefore did not spend the entire 2 min of 
the probe trial exploring the board. Therefore, a secondary calculation was carried out 
to ensure that the data presented was representative of the actual test time that mice 
spent exploring and was not skewed by an extended latency to leave the central start 
zone. This was calculated as [time (s) in target zone/(120 s – latency (s) to leave the 
centre zone] x 100. Importantly, this secondary measure did not change the 
significance findings of the initial target zone results (data not shown).  
The first 30 s and second 30 s bins of the CB probe were also analysed to 
investigate retrieval memory and perseverance, respectively. One sample t-test for the 
time spent in the target zone as a percentage of 30 s indicates that all mice 
demonstrated intact retrieval memory in the first 30 s [WT-VEH; t(14) = 4.8, p < .001, 
APPxPS1-VEH; t(9) = 3.1, p = .01, WT-CBD; t(12) = 5.3, p < .001, APPxPS1-CBD; 
t(9) = 3.3, p = .009; Table 4]. Interestingly, when investigating the second 30 s time 
bin as an indication of perseverance, it was evident that while WT mice persevered to 
find the food reward, i.e. spent significantly more than 12.5% of the second 30 s in the 
target zone [one sample t-test: WT-VEH; t(14) = 3.3, p = .005, WT-CBD; t(12) = 3.3, 
p = .006], APPxPS1 mice regardless of treatment did not [APPxPS1-VEH; t(9) = 1.8, 
p = .1, APPxPS1-CBD; t(9) = 1.2, p = .3; Table 4].  
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Similar analyses were also conducted for the rCB probe. All experimental groups 
(weak trend for APPxPS1-CBD mice), had a preference for the target zone [WT-VEH; 
t(14) = 2.9, p = .01, APPxPS1-VEH; t(9) = 2.5, p = .03, WT-CBD; t(12) = 4.6, p = 
.001, APPxPS1-CBD; t(10) = 1.9, p = .09; Figure 20B]. No change in results became 
apparent when taking into consideration the latency of mice to leave the central start 
zone (data not shown). In addition, all mice demonstrated intact retrieval memory in 
the reversal probe (first 30 s block) [WT-VEH; t(14) = 2.8, p < .01, APPxPS1-VEH; 
t(8) = 3.4, p = .01, WT-CBD; t(12) = 4.3, p = .001, APPxPS1-CBD; t(9) = 2.7, p = .03; 
Table 4]. However, as seen in the CB probe, while WT mice persevered to find the 
food reward in the second 30 s block [WT-VEH; t(14) = 3.7, p = .002, WT-CBD; t(12) 
= 2.8, p = .02], APPxPS1 mice again did not [APPxPS1-VEH; t(8) = 1.8, p = .1, 
APPxPS1-CBD; t(9) = 1.7, p = .1; Table 4].  
81 
Figure 20A-B: Spatial memory in the cheeseboard (CB) probe and reversal 
cheeseboard (rCB) probe. 
A) Percentage of time spent [%] in the target zone for the CB probe and B) for the 
rCB probe. Data for non-transgenic wild type-like (WT) control and double 
transgenic APPSwe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle 
(VEH) or cannabidiol (CBD) are shown as means + SEM. Significant t-test results 
are indicated by ‘+’ (+p < .05, ++ p < .01 and +++p < .001) and a trend is indicated 
by ‘p = .09’
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Table 4: Retrieval memory and perseverance in the cheeseboard (CB) probe and 
reversal cheeseboard (rCB) probe. 
Data shown as percentage of time spent in the target zone in the first and second 30 s 
of each probe test for non-transgenic wild type-like (WT) control and double 
transgenic APPSwe/PS1ΔE9 (APPxPS1) female mice treated with either vehicle 
(VEH) or cannabidiol (CBD). Data are presented as mean ± SEM. Significant t-test 
results are shown by ‘+’ (+p < .05, ++p < .01, and +++p < .001). First 30 s block data 
represents retrieval memory, second 30 s block data represents perseverance.  
3.5 Prepulse inhibition 
3.5.1 Acoustic startle response 
The ASR of all mice was not significantly different as there were no main effects 
of ‘genotype’ or ‘treatment’ (all p’s > .05). All mice responded to the startle pulses 
with increasing startle intensities (70 dB, to 100 dB, to 120 dB), with the 120 dB startle 
pulse producing the greatest startle responses [RM ANOVA for ‘startle intensity’: 
F(2,90) = 411.2, p < .001; no interactions with ‘genotype’ or ‘treatment’, all p’s > .05; 
Figure 21A]. Also, all mice regardless of experimental condition displayed decreasing 
ASR across the three blocks of five 120 dB pulses each, confirming that all mice 
habituated to the 120 dB startle pulse, regardless of genotype or treatment [RM 
ANOVA for ‘startle block’: F(2,90) = 25.4, p < .001; no interactions with ‘genotype’ 
or ‘treatment’, all p’s > .05; data not shown]. 
WT-VEH APPxPS1-VEH WT-CBD APPxPS1-CBD 
CB probe - % time spent in target zone 
First 30 s 27.5 ± 3.1+++ 30.3 ± 5.8+ 34.8 ± 4.2+++ 34.2 ± 6.5++ 
Second 30 s 31.8 ± 5.9++ 28.9 ± 8.9 22.6 ± 3.0++ 21.0 ± 7.1 
rCB probe - % time spent in target zone 
First 30 s 29.5 ± 6.0+ 27.1 ± 4.3+ 30.2 ± 4.1++ 34.0 ± 8.0+ 
Second 30 s 26.3 ± 3.8+ 19.1 ± 3.8 21.6 ± 3.2+ 27.2 ± 8.7 
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3.5.2 Prepulse inhibition 
Three-way RM ANOVA found that as prepulse intensities increased, the %PPI 
(averaged across ISI) of all mice became more robust [‘prepulse intensity’: F(2,90) = 
166.7, p < .001; Figure 21B]; i.e. sensorimotor gating increased with prepulse 
intensities. Importantly, a significant ‘genotype’ by ‘prepulse intensity’ interaction 
[F(2,90) = 8.3, p < .001; Figure 21B] was found as well as a genotype difference for 
the average %PPI [F(1,45) = 5.5, p = .02; Figure 21C]. Two-way ANOVA was used 
to investigate this interaction, with data split by ‘prepulse intensity’. Significant effects 
of ‘genotype’ were found for %PPI at prepulse intensities of 82 dB [F(1,45) = 9.8, p 
=.003] and of 86 dB [F(1,45) = 9.3, p =.004] (with p > .05 at 74 dB; Figure 21B) with 
APPxPS1 females showing reduced prepulse inhibition compared to WT females. 
CBD treatment had no overall effect on sensorimotor gating and also did not change 
the genotype effect (i.e. no overall ‘treatment’ effect and no ‘genotype’ by ‘treatment’ 
interactions for any prepulse intensity; all p’s > .05). 
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Figure 21A-C: Acoustic startle response (ASR) and sensorimotor gating (PPI). 
A) ASR to increasing startle pulse intensity (70/100/120 dB), B) percentage prepulse 
inhibition [%PPI] averaged over trials for increasing prepulse intensities (74/82/86 
dB) and C) %PPI averaged over prepulse intensity and interstimulus interval (ISI). 
Data for non-transgenic wild type-like (WT) control and double transgenic APPSwe/
PS1ΔE9 (APPxPS1) female mice treated with either vehicle (VEH) or cannabidiol 
(CBD) are shown as means + SEM. Significant ‘genotype’ effects are indicated with 
‘*’ (*p < .05) and RM effects are indicated by ‘^’ (^^^p < .001).
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Chapter 4: Discussion and Conclusions 
4.1 Summary 
The research conducted as part of this thesis investigated for the first time the 
behavioural effects of chronic administration of 5 mg/kg CBD in 12-month-old female 
double transgenic APPxPS1 mice. Behavioural differences in APPxPS1 mice 
compared to WT mice were detected and CBD impacted upon some of those 
differences. Namely, the main findings were; i) APPxPS1 mice exhibited a hyper-
locomotive phenotype in the LD test regardless of treatment; ii) CBD treatment 
increased rearing of both WT and APPxPS1 mice in the dark zone of the LD test; iii) 
APPxPS1 mice spent more time in the dark zone compared to WT littermates (and 
tended to travel further in the dark zone); iv) CBD-treated APPxPS1 females were the 
only mice to show a preference for the dark zone; v) all mice showed similar motor 
abilities in the pole test and in the accelerod with the exception that APPxPS1 mice 
regardless of treatment fell off the accelerod sooner in their worst trial compared to 
WT mice; vi) APPxPS1 mice developed a deficit in object recognition memory in 
NORT, which was reversed by CBD treatment; vii) APPxPS1 mice although being 
slower than WT mice, showed intact spatial learning and memory but exhibited 
impaired perseverance in the CB probe and rCB probe; viii) the ASR of all mice was 
similar but APPxPS1 transgenic females regardless of treatment showed a deficit in 
PPI. Thus, most important for the study rationale was the finding that CBD treatment 
reversed the cognitive deficits of APPxPS1 transgenic females in the object 
recognition memory test.  
Wandering, restlessness and agitation are commonly seen in patients of AD, as 
previously reviewed (Alzheimer’s Association 2018; AIHW 2012). Accordingly, task-
dependent hyper-locomotive behaviours have been reported in the APPxPS1 model 
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previously in both 7-month-old male and female mice (Cheng et al. 2013; Cheng et al. 
2014b), and were replicated in this study in the LD test. APPxPS1 females displayed 
increased locomotion in the entire arena of the LD test compared to WT littermates, 
and CBD treatment did not affect this. Importantly, this hyper-locomotion was also 
evident when analysing locomotion in the dark zone alone, indicating that anxiety 
levels did not impact upon the hyper-locomotive phenotype of APPxPS1 mice, as 
behaviours in the less aversive dark zone are free of state (spatio-temporal) anxiety 
(Crawley 1985; Ramos 2008).  
 CBD had no effect on the locomotion of WT mice nor on the hyper-locomotive 
phenotype of APPxPS1 mice. This is in line with other studies which found that, e.g. 
acute administration of 60 mg/kg CBD and acute dosing with 10 mg/kg CBD had nil 
effect on the locomotion of WT male Swiss mice (Moreira & Guimarães 2005) and 
male C57BL/6 mice respectively (Todd & Arnold 2016). Furthermore, 1, 5, 10 and 50 
mg/kg CBD given acutely or for 15 days or 21 days also did not affect the locomotion 
of male C57BL/6JArc mice (Long et al. 2010). Although CBD did not affect the hyper-
locomotive phenotype of APPxPS1 mice in this study, it is interesting to note that CBD 
can impact on hyper-locomotion evident in other mouse model systems. For example, 
acute administration of 60 mg/kg CBD has been found to effectively reduce ketamine- 
(an NMDA-receptor antagonist) and amphetamine- (an indirect dopaminergic agonist) 
induced hyper-locomotion of male Swiss mice (Moreira & Guimarães 2005), and 1.25-
20 mg/kg CBD given acutely also reduced ischaemia-induced hyper-locomotion in 
gerbils (Braida et al. 2003). The mechanism by which CBD altered these drug-induced 
and ischaemia-induced hyper-locomotion is not clear (Braida et al. 2003; Moreira & 
Guimarães 2005), and the mechanism by which the APPxPS1 transgene induces 
hyper-locomotion in APPxPS1 mice has not yet been studied. It is feasible that the 
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mechanism inducing the hyper-locomotion in APPxPS1 mice is distinct from the 
mechanism by which CBD reversed the hyper-locomotion in the mentioned studies, 
which would explain why CBD did not have an effect on the hyper-locomotive 
phenotype of APPxPS1 mice in this study. Thus, more research into the possibility of 
CBD reducing APPxPS1 hyper-locomotion is required. 
 Exploration was also examined in the LD test. CBD treatment increased the 
frequency of rearing of both WT and transgenic mice specifically in the dark zone, 
indicating that the mice treated with CBD were more inclined to explore in the less 
aversive dark zone than their vehicle-treated counterparts. A previous study found that 
rearing was unaffected in the open field (OF) test after both acute and chronic 
administration of 1, 5, 10 and 50 mg/kg body weight CBD in 12-14-week-old male 
C57BL/6JArc mice (Long et al. 2010). Interestingly, an acute dosage of 50 mg/kg 
CBD increased the OF exploration of mutant mice in a neuregulin 1 mouse model of 
schizophrenia (C57BL/6JArc background, males aged 21 ± 3 weeks), however, this 
effect disappeared after chronic CBD treatment (Long et al. 2012). This indicates that 
the current study revealed new insights into the complex, potentially task- and strain-
specific effects of CBD on exploration. Furthermore, mice of the previously mentioned 
studies were much younger (and also male) so the age at time of treatment and sex 
could potentially be another reason for the differences between the current and past 
studies.     
 Anxiety was also measured in the LD test. APPxPS1 mice showed an aversion to 
the more anxiety-producing light zone more so than their WT counterparts without 
CBD impacting on this, which is suggestive of an anxiogenic phenotype of APPxPS1 
females. It was important to determine the anxiety phenotype of these mice as stress 
and anxiety can impact upon the behavioural performance of experimental mice 
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(Brinks et al. 2007; Harrison, Hosseini & McDonald 2009), and could have therefore 
been a confounding factor for the other tests of cognition in this study; therefore 
anxiety was investigated here as a control measure. In particular, any effect of the 
APPxPS1 transgene or of CBD on anxiety in this study needed to be determined to 
ensure that the subsequent behavioural results found were true indications of the test 
outcome, and not the result of a confounding anxiety phenotype of APPxPS1 mice or 
of the effect of CBD on anxiety. Thus, as this study found that the APPxPS1 transgene  
affected anxiety in the experimental mice, behavioural results in latter tests had to be 
interpreted accordingly. Furthermore, it is known that anxiety can be present in AD 
patients (Alzheimer’s Association 2018) and is reduced in APPxPS1 mice (Cheng et 
al. 2014b; discussed further below), adding further to the rationale to anxiety-related 
behaviours in the current study.  
  As mentioned, APPxPS1 mice showed an aversion to the light zone more so than 
WT mice, suggesting that APPxPS1 females had an anxiogenic phenotype. This is 
contradictory to the findings of a previous study, in which 7-month-old female 
APPxPS1 mice spent more time in the light zone, indicative of an anxiolytic phenotype 
(Cheng et al. 2014b). Importantly, the interpretation of the anxiety-related results in 
the LD paradigm in this study is confounded by the finding that the control WT mice 
did not show the expected, and previously reported preference for the less aversive 
dark zone (Cheng et al. 2014b). Instead, WT mice of both treatment groups failed to 
develop a preference for the dark zone. This complicates findings as it suggests that 
the paradigm failed to induce state anxiety in the control mice as it should have; hence, 
any results found for either experimental condition of treatment or genotype for 
anxiety should be interpreted with caution.  
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 In accordance with the above, while this study found that CBD had no effect on 
anxiety across both WT and APPxPS1 mice, these results need to be interpreted 
carefully. Previous preclinical studies have shown that chronically administered CBD 
can produce anxiolytic-like effects. For example, administration of 20 mg/kg CBD 
daily for 6 weeks in male and female C57BL/6J mice resulted reduced EPM anxiety 
compared to vehicle-treated mice (this was a task-specific effect as no effects on 
anxiety were found for the LD test or OF; Schleicher et al. (2019)). However, other 
studies indicate that acute, chronic and long-term administration of CBD has no effect 
on anxiety. For example, a single dose of 10 mg/kg CBD had no effect on OF anxiety 
of 14-week-old male C57BL/6 mice (Todd & Arnold 2016), and chronic daily 
administration of 20 mg/kg CBD had no effect on the levels of EPM anxiety in 24 ± 1 
weeks old male WT and APPxPS1 mice (Cheng et al. 2014a). Furthermore, long-term 
oral administration of the same dosage of CBD also had no effect on 10-month-old 
male WT and APPxPS1 mice (Cheng et al. 2014c). Furthermore, it has been suggested 
that the anxiolytic effects of CBD may only be evident after an external stressor has 
been applied, for example, following daily unpredictable stress (Campos et al. 2013). 
Accordingly, it is evident that the effect of chronic CBD on anxiety appears to be 
complex and likely to be dose- and paradigm-specific. Interestingly, APPxPS1 mice 
chronically treated with CBD were the only mice with a preference for the dark zone, 
suggesting an anxiogenic effect of CBD specifically for this experimental group. 
However as mentioned, care must be taken in this interpretation since the LD paradigm 
did not work for the WT mice. Nonetheless, CBD is known to exhibit a biphasic dose-
response in relation to anxiety in both humans and in animals including experimental 
mice (Rey et al. 2012; Zuardi et al. 2017). For example, an acute dosage of 300 mg 
CBD prior to an anxiety-inducing task (public speaking) reduced subjective anxiety 
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measures in healthy human subjects following the test, while 100 mg and 900 mg of 
CBD did not (Zuardi et al. 2017). Thus, it is possible that while in the Cheng et al. 
(2014a) a higher dosage of 20 mg/kg CBD did not affect anxiety in the APPxPS1 
model, the low dosage of 5 mg/kg CBD in this study increased anxiety in the transgenic 
mice due to the biphasic properties of CBD on anxiety (although more research would 
be required as to why the anxiety of WT mice treated with CBD was unaffected). 
Furthermore, a different paradigm, and age and gender of mouse were used in these 
studies, which could contribute to the difference in findings here.  
 Motor function impairment is not always reported in patients with AD, although it 
has been more recently considered as an associated non-cognitive symptom of the 
disease (Buchman & Bennett 2011). In our study, all mice performed equally well in 
the pole test. In the accelerod, APPxPS1 mice fell off the accelerod sooner than WT 
mice on their worst performing trial, however, averaged across the two days, all mice 
showed similar motor performance regardless of the experimental condition. This 
moderate deficit is potentially due to an increase in slipping off the rod, rather than 
due to a distinct deficit in motor coordination and balance as the best performance was 
similar across experimental groups. Supporting this idea is the finding from a previous 
study in which male and female APPxPS1 mice at 6 months of age tended (not 
significant) to slip more often than WT mice in the balance beam test (Kuwabara et al. 
2014). However, a more reliable measure of motor function is looking at the average 
across a number of trials (Kovács & Pearce 2013) and perhaps of the best performing 
trial. As stated earlier, these measures of motor performance were not different 
between WT and APPxPS1 transgenic mice. This is in line with the majority of 
previous findings that there is no motor phenotype in this model when using an 
accelerating rotarod paradigm (Kemppainen et al. 2014; Lalonde, Kim & Fukuchi 
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2004). For example, 7-month-old male and female APPxPS1 mice have been found to 
show intact motor abilities in an accelerating rotarod paradigm, and in the grip 
strength, stationary beam and coat hanger tests (Lalonde, Kim & Fukuchi 2004), and 
3.5-month-old male APPxPS1 mice had wild type-like function in an accelerod 
paradigm (while APPxPS1 mice with induced transient global ischaemia did not; 
Kemppainen et al. (2014)). However, other studies have found conflicting evidence as 
to the presence of motor deficits in the APPxPS1 model. For example, 6-month-old 
males and females had significant motor deficits in a non-accelerating rotarod 
paradigm (Kuwabara et al. 2014). It seems that the conflicting evidence in part may 
be due to task-specific findings; those using a non-accelerating rotarod found a motor 
deficit in APPxPS1 mice (Kuwabara et al. 2014), while those using an accelerating 
paradigm (including this study) did not (Kemppainen et al. 2014; Lalonde, Kim & 
Fukuchi 2004). Non-accelerating paradigms are more so a test of endurance, while 
accelerating rotarod paradigms are a more reliable test of motor function (Deacon 
2013). Further, the rate of acceleration in accelerating paradigms must be controlled 
to prevent fatigue confounding the results. Thus, the differences in the two rotarod 
paradigms could explain the conflicting evidence as to the motor function of APPxPS1 
mice. 
 Moreover, acute and chronic dosages of CBD have previously demonstrated few 
extrapyramidal side effects on motor function (Iffland & Grotenhermen 2017). 
Accordingly, chronic CBD had no impact upon the ability of mice to complete the pole 
test or accelerod paradigms in this study, indicating that CBD had no adverse side 
effects on the motor function of WT or APPxPS1 transgenic mice. This is in line with 
previous studies. For example, 20, 40 or 80 mg/kg CBD administered 1, 2 or 4 h prior 
to rotarod testing did not have any effect on motor performance in male Swiss mice 
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(Ten Ham & De Jong 1975). Also, 50, 100 or 200 mg/kg CBD administered 1 h prior 
to accelerod testing in adult male Wistar Kyoto rats had no effect on motor function 
(aside from the finding that 100 mg/kg CBD affected the number of foot slips of the 
rats; Jones et al. (2012)). Also, in human patients with Parkinson’s disease, 4 weeks 
of daily treatment with a flexible dosage of oral CBD (starting at 150 mg) in addition 
to usual therapy did not worsen motor function symptoms (Zuardi et al. 2009).  
 Recognition impairments are common symptoms of AD, particularly in the 
advanced symptomatic stage, with patients often having issues recognising faces and 
objects (Alzheimer’s Association 2018). Accordingly, the current study detected a 
novel object recognition deficit in 12-month-old APPxPS1 females in the NORT 
paradigm. This finding has been demonstrated in the APPxPS1 model before with 5-
6-month-old males developing novel object recognition impairments (Cheng et al. 
2014a). Furthermore, object recognition impairments in female APPxPS1 mice have 
been reported to be robustly evident at 12 months of age in the two object recognition 
test (within a V-maze, rather than a square arena as in the NORT), which correlates 
with the advanced symptomatic stage of AD (Aso, Andrés-Benito & Ferrer 2016). It 
is important to note that object recognition memory deficits of APPxPS1 transgenic 
mice appear to be sex- and test protocol-dependent. For example, as mentioned above 
Cheng et al. (2014a) found object recognition impairments in males in the NORT 
paradigm in a square arena, yet Cheng et al. (2014b) and Jardanhazi-Kurutz et al. 
(2010) found that 7-month-old and 12-month-old females had intact object recognition 
memory, respectively, as demonstrated by a preference of greater than 50% for the 
novel object in  the NORT, (although the preference for the novel object in the latter 
study was reduced compared to the control mice). This highlights a difference in the 
recognition memory between the two sexes as found in the same paradigm. Also, when 
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using the two object recognition test in a V-maze, Aso, Andrés-Benito and Ferrer 
(2016) found a recognition impairment in 12-month-old females as mentioned, 
showing that the paradigm used affects the observance of recognition deficits. Thus, 
this study is the first to find a robust memory impairment in the NORT paradigm for 
12-month-old female APPxPS1 mice. 
 Importantly, chronic treatment with CBD was able to rescue the novel object 
recognition deficit in the current study, i.e. CBD-treated transgenic mice developed a 
preference for the novel object. Thus, low dose CBD was able to reverse the object 
recognition deficit of 12-month-old APPxPS1 females, in line with earlier studies 
using a higher dosage of 20 mg/kg body weight CBD in 5-6-month old males (Cheng 
et al. 2014a). Interestingly, impairments to object recognition have been linked to 
glutamatergic dysfunction and inhibition of the glutamate transporter 1 (Tian et al. 
2019), with preclinical studies showing that antagonism of the glutamate NMDA 
receptor via memantine can improve object recognition memory (Scholtzova et al. 
2008). Importantly, CBD has been found to interact with NMDA receptors (Hallak et 
al. 2011), indicating that CBD may have reversed the object recognition deficits of 
APPxPS1 mice in this study through the glutamatergic system.      
 Spatial disorientation is another symptom commonly seen in patients with AD 
(Alzheimer’s Association 2018). Accordingly, spatial learning and memory of 
APPxPS1 mice was investigated in this study in the CB paradigm. The current study 
found that during the training phase of the CB, all mice acquired the task (learned the 
position of the baited well) for both CB and rCB training. APPxPS1 mice learned in a 
similar way as WT mice did, which is evidenced by a paralleled decrease in the latency 
to find the reward over days for both genotypes. This indicates intact spatial learning 
abilities for APPxPS1 females. Transgenic mice took generally longer per day to find 
 94 
the position of the food reward which could be related to a motor deficit or a reduction 
in the motivation of the mice to find the reward (Zhang et al. 2011). Analysing the CB 
test in more detail revealed that the average speed of mice on the board during CB 
training and rCB training was reduced in APPxPS1 mice. The differences seen in speed 
appear unlikely to be linked to varying levels of motivation to find the food reward. 
All mice showed motivation to consume the food reward during habituation, and the 
few mice, which refused to drink the food reward during training were not of a 
particular genotype. Importantly, the CB is known to be a less-stressful alternative to 
the MWM (Grech et al. 2019), which is significant in this study as we found an 
anxiogenic-like response of the APPxPS1 mice in the LD test; thus, anxiety should not 
have impacted upon the learning of mice either. Also, chronic CBD had no effect on 
spatial learning, and importantly has previously been shown to have no effect on 
memory in control animals (Fagherazzi et al. 2012). 
 We also investigated intermediate-term and long-term memory of the mice in CB 
and rCB training, as defined by the ITI employed and outlined already in section 2.3.5, 
i.e. the intermediate-term memory of mice was determined by the average latency of 
trial 2 and 3 (~ 20 min following the previous trial), and the long-term reference 
memory of mice was determined by the latency of trial 1 only (~24 h following the 
last trial of the day prior). Short-term, intermediate-term and long-term memory each 
have temporal constraints and have distinct molecular characteristics. For example, 
short-term memory transpires after only a few minutes and is independent of protein 
synthesis and gene transcription, intermediate-term memory occurs over several hours 
and is dependent on protein synthesis but not gene transcription, and long-term 
memory occurs after a period of 24 h and is gene transcription-dependent (Kandel 
2001; Stough, Shobe & Carew 2006; Taglialatela et al. 2009). Thus, the interval used 
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between training trials (i.e. 20 min between trials of each day, and 24 h between the 
last and first trial of successive days) can inform which kind of memory impairment 
is present and therefore which molecular mechanism is impaired, if any (Taglialatela 
et al. 2009). Thus, when considering the intermediate-term memory and the long-term 
reference memory of mice in this study, it became apparent that, similarly to the overall 
learning performance, all mice showed a decrease in the latency to find the reward 
across days, and APPxPS1 mice took longer per day to find the food reward. Thus, 
learning performance based on intermediate-term memory and reference memory was 
not affected by the APPxPS1 genotype during both CB and rCB training. Also, CBD 
had no effect on the two types of spatial learning of mice in both the CB and the rCB 
training sessions. Investigating CB learning in terms of intermediate-term and long-
term memory is relatively new and has only recently been described in our laboratory 
in a mouse model of motor neuron disease (Kreilaus et al. 2019); thus, this is the first 
study to identify that the intermediate-term and long-term retention learning memory 
of 12-month-old APPxPS1 females is wild-type like. 
 In the CB and rCB probe, all mice recognised their target zone above chance for 
the 2 min duration of the trial (there was only a weak trend for a target zone preference 
in APPxPS1-CBD mice in the rCB probe; this was most likely driven by a large SEM 
due to a statistical outlier, rather than a deficit in memory performance. The statistical 
outlier was not excluded from analysis as it performed the task properly when the test 
video was reviewed). This indicates that APPxPS1 mice did not have a spatial memory 
impairment, which is converse to what has been found in the past in the CB and other 
tests of spatial memory. For example, the CB has previously been shown to reliably 
detect cognitive deficits in 8-9-month-old APPxPS1 females, which did not show a 
preference for the target zone during the rCB probe (Cheng et al. 2014b). APPxPS1 
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mice also show spatial learning and retention deficits in other tests of spatial memory. 
For example, 12-month-old APPxPS1 female mice (on a C57BL/6 background) show 
a reduced latency during training to find the platform in the hidden MWM, and also 
spend less time in the target zone during the probe trial (Zhang et al. 2011). 18-month-
old male APPxPS1 mice have demonstrated spatial impairments in the early stages of 
training in the MWM, with less accurate memory for the platform location on the first 
day of training, and also towards the end of training as they travel nearly twice as far 
as WT mice to find the platform (Savonenko et al. 2005). 16-month-old APPxPS1 
mice of both sexes have also demonstrated impairments in the Barnes maze, whereby 
they showed impaired acquisition learning and were less likely to use a spatial search 
strategy compared to WT mice, and also showed a deficit in memory in probe tests 
(O’Leary & Brown 2009). However, it is important to note that caution should be used 
when comparing the findings from studies using the MWM and Barnes maze with 
findings from studies using the CB, as the motivation involved in the task is different, 
i.e. the motivation to avoid drowning and to escape are utilised in the MWM (Grech 
et al. 2019) and the Barnes maze (O’Leary & Brown 2009), while positive 
reinforcement is used in the CB. Thus, it is clear that spatial memory impairments have 
been found in this model before, and it is especially important to suggest why this 
study did not find the same spatial memory impairments that Cheng et al. (2014b) did 
in APPxPS1 females in the CB (since the same paradigm was used). Specific protocols 
can impact upon results of the same test (Post et al. 2011), and it is important to note 
that there were significant differences between this study and Cheng et al. (2014b). 
Firstly, the laboratories in which these experiments were conducted were different, 
and secondly the experimenter in this study was female, while the experimenter in 
Cheng et al. (2014b) was male. Differing laboratory and experimenter conditions can 
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have an impact on the baseline behaviour of mice (Lewejohann et al. 2006), with 
evidence showing that male-related stimuli can cause physiological stress in rodents 
(Sorge et al. 2014). Evidence of these differences between the current study and Cheng 
et al. is the fact that the 12-month-old WT mice in this study only required 5 days of 
CB training and 4 days of rCB training to acquire the task, while those in Cheng et al. 
received 9 days of CB training and 4 days rCB training, i.e. mice in the Cheng et al. 
study required longer training. It is speculated that this may be caused by the difference 
between the laboratory and experimenter of each study, with the learning of the task 
made harder for the mice in the Cheng et al. study due to the male-related stimuli and 
differences in cue presentation and noise in the facility, thereby altering the protocol 
of the CB, which could account for the differences found for spatial memory.  
 To further investigate the spatial memory in these mice, we took a relatively novel 
approach for CB analysis and examined the preference of mice for their target zone in 
the first 30 s and the second 30 s to identify retrieval memory and perseverative 
behaviour, similar to what was outlined in a recent study (Grech et al. 2019). Briefly, 
and as outlined in section 2.3.5, mice that showed a preference for the target zone in 
the first 30 s are suggested to have intact retrieval memory, while those that do not 
have a deficit. A preference for the target zone over next 30 s indicates persistence to 
find the food reward, while no preference indicates either i) lack of persistence or ii) 
cognitive flexibility in adaptation to the lack of food reward (since the probe trial can 
be considered as an extinction trial; Grech et al. (2019)). The current study found that 
all mice regardless of experimental condition exhibited intact retrieval memory in the 
CB and rCB probe trial. CBD had no effect on retrieval memory. When analysing the 
memory performance in the second 30 s of the CB and rCB probe trials, only WT mice 
showed a preference for their target zone, indicating perseverance to find the food 
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reward. However, APPxPS1 mice of both treatment groups no longer showed a 
preference for the target zone, which as proposed could be an indication of cognitive 
flexibility in adaptation to the lack of the food reward (Grech et al. 2019), or simply a 
lack of persistence. As this is a very novel approach at investigating the spatial memory 
of mice in the CB, further investigation is required to determine exactly what the lack 
of a preference for the target zone in the second 30 s means. Future analysis of search 
patterns, i.e. allocentric (using external cues or landmarks in relation to each other to 
navigate, independent of self) versus egocentric (based on directional (left-right) 
responses to navigate, independent of environmental cues) search strategies, could 
help answer this. 
 Sensorimotor gating is the filtering of extraneous information and can be assessed 
in both humans and in animal models in PPI paradigms, and was assessed in this study 
as there is some evidence that PPI is affected in AD. The present study found that the 
average %PPI of APPxPS1 females was reduced compared to littermates, indicating a 
robust PPI deficit. This is in line with Wang et al. (2012) which found robust PPI 
deficits as early as 7 months in female APPxPS1 mice (generated on mixed B6SJLF1 
x B6D2F1 x Swiss Webster background), which were associated with cerebral 
amyloid neuropathology. However, these findings are converse to the study by Cheng 
et al. (2014b) which found that PPI was largely unaffected in female 46 ± 1 week old  
female APPxPS1 mice, with deficits found at the 128 ms ISI only. Furthermore, 
analysing the PPI response in more detail, the genotype effect was evident at the more 
robust prepulse intensities of 82 dB and 86 dB, which are significantly above the 
background noise. Similar to Wang et al. (2012), the PPI deficit of APPxPS1 females 
was not accompanied by any changes in the baseline startle response or habituation 
thereof. The conflicting preclinical evidence that PPI is affected in mouse models of 
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AD is also seen in clinical trials in AD patients. This conflict in evidence may be due 
to studies differentially grouping patients with MCI together with patients with AD, 
versus analysing these groups separately. For example, patients with mild AD or MCI 
(grouped together) were shown to have normal PPI in a passive acoustic PPI paradigm 
compared to healthy controls (Hejl et al. 2004), but in another study testing acoustic 
PPI, patients with ‘early dementia of Alzheimer’s type’ had a gating deficit, while 
those with MCI (analysed as a separate group) had gating facilitation. Furthermore, a 
study using a double-click paradigm found that AD patients have suppression of the 
P50 event-related potential following the second click (a sensory gating deficit; Jessen 
et al. (2001)). It has been suggested that PPI deficits in early stage AD patients could 
be due to disturbed regulation of the limbic cortico-striato-pallido-pontine circuitry 
(Ueki et al. 2006), or due to cholinergic dysfunction and alpha-7 nicotinic receptor loss 
(Jessen et al. 2001), 
 Chronic 5 mg/kg CBD did not affect the ASR or PPI of experimental mice and 
also did not reverse the PPI deficit in APPxPS1 transgenic mice. Previous studies have 
demonstrated that acute CBD is able to attenuate pharmacologically induced 
disruptions of PPI, without affecting any aspects of sensorimotor gating in control 
mice. For example, pretreatment (single i.p. injection) of 30 and 60 mg/kg CBD 
reduced the PPI deficits in amphetamine-treated mice (Pedrazzi et al. 2015), and a 
single dose of 5 mg/kg CBD reversed PPI deficits induced by the noncompetitive 
NMDA receptor antagonist MK-801 (Long, Malone & Taylor 2006). These studies 
suggest that CBD may have some capabilities to reverse particular PPI deficits without 
side effects. However, other studies have found no beneficial effects of CBD on PPI 
deficits. For example, 3 and 10 mg/kg CBD administered to an MK-801-induced rat 
model of schizophrenia was unable to recover PPI deficits and actually caused PPI 
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deficits in the control group (Gururajan, Taylor & Malone 2011). Another study 
administering 20 mg/kg CBD i.p. daily for 8.5 weeks caused a PPI deficit at prepulse 
intensities of 75 dB and 80 dB in 6-month-old C57BL/6J mice, suggesting a possible 
side effect of the drug (Schleicher et al. 2019). The discrepancies in the findings of 
CBD effects on PPI may be due to the fact that PPI test outcomes are heavily dependent 
on the protocol characteristics used in each study (Karl et al. 2011), with importance 
being placed on the ISI, duration and intensity of the prepulse and startle pulse, the 
total protocol duration and the particular algorithms for calculating PPI and 
interpretation of results, as well as habituation procedures prior to PPI testing 
(Swerdlow, Braff & Geyer 2000). Furthermore, the effect of CBD on PPI in the 
mentioned studies were investigating the effects of acute CBD, rather than chronic 
administration of CBD as investigated in this study. Thus, different protocol 
characteristics used in each study may account for the differing results found, i.e. why 
CBD did not reverse APPxPS1 PPI deficits in this study when it has shown the 
potential to previously.  
 
4.2 Limitations and future perspectives 
 Some limitations affected this study. Firstly, the present study did not investigate 
male mice for feasibility reasons. It is known that there is a sexual dimorphism profile 
of the AD-relevant pathologies (Aβ, NFT and pro-inflammatory cytokines) for this 
model (Jiao et al. 2016) and behavioural differences between male and female 
APPxPS1 mice (Cheng et al. 2013; Cheng et al. 2014b). Secondly, this study is limited 
in that it only investigated the effects of CBD in an animal model of amyloidosis 
without an investigation of the effects of CBD on tau pathology. Future investigation 
could include a tau pathology animal model, or a model with both amyloid and tau 
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pathology, for a more comprehensive investigation of the therapeutic potential of low 
dose CBD for AD. Also, future studies could investigate the effects of chronic CBD 
administration in APPxPS1 mice at an earlier age (relevant for early stage or pre-AD), 
to determine the effectiveness of CBD treatment prior to AD symptom onset, or could 
investigate higher dosages of CBD. 
 There are numerous other aspects of this study that can be followed up in future 
studies. Firstly, further analysis into the search patterns of mice during the CB and rCB 
could be conducted to determine any deficits in allocentric or egocentric navigational 
strategies that might explain the lack of perseverance in APPxPS1 mice during probe 
trials. Secondly, while the brain tissue of test mice was collected at the conclusion of 
behavioural testing, it was not analysed as part of this thesis due to time constraints. 
An investigation of the neuropathological markers of AD in the test mice to determine 
the effect of 5 mg/kg body weight CBD at the molecular level in the APPxPS1 mouse 
model of AD will likely be performed as a follow up study to this thesis. It is likely 
that quantification of soluble and insoluble Aβ40 and Aβ42 in the PFC, hippocampus 
and cerebellum will be determined through ELISA techniques in this future 
investigation. Future analysis would also investigate levels of IBA-1 to determine 
microglial activity, and levels of TNF-α and IL-1β as markers of neuroinflammation. 
These molecular investigations would add insight into the effect of chronic 5 mg/kg 
CBD on the molecular markers of AD in the APPxPS1 model. 
 A major limitation of this study was the failure of the LD test to induce state 
anxiety in the WT mice. Numerous aspects of this study’s design of the LD test were 
reconsidered to determine an explanation for this failure of WT mice to show a 
preference for the dark zone. Firstly, it was hypothesised that perhaps the mice were 
showing risk-assessment behaviour around the passage opening between the two 
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zones, distorting the ratio of the time spent in either zone. To assess the time spent and 
distance travelled in the more distal parts of the zones, a central exclusion zone was 
created in the analysis software, resulting in three zones. The central exclusion zone 
data was excluded from analysis, with the new, smaller light and dark zones used when 
reanalysing anxiety behaviours in the LD test. However, this reanalysis did not alter 
the previous findings, suggesting that the activity of mice in the central exclusion zone 
did not cause the unexpected findings; thus, the failure for the WT mice in this test is 
due to some other factor. 
 In this context it is important to mention that in line with other experiments in our 
laboratory, tests of anxiety are generally conducted at the start of a test battery, so that 
test mice are naïve with only a limited amount of handling prior to anxiety-related 
testing in the LD paradigm. This is important because the handling of experimental 
animals during testing is a source of stress that can impair their responses (Gouveia & 
Hurst 2017). Furthermore, it is known that the changing of cages of test mice can 
increase general activity and stress levels (Bailey & Crawley 2009), therefore, animal 
husbandry was not carried out on experimental days or only after testing had been 
completed for that day. Furthermore, as anxiety was one of the main parameters being 
assessed in the LD paradigm, mice were given a full hour of habituation to the testing 
room prior to the LD to reduce any stress caused by transport from the animal housing 
facility (Bailey & Crawley 2009). Thus, while all aspects of the LD test were carefully 
considered, an explanation for the failure of WT mice to show a preference for the 




 This study found that 12-month-old female APPxPS1 transgenic mice were hyper-
locomotive and showed no motor deficits. Spatial learning and memory were not 
affected in AD transgenic females, but transgenic mice showed object recognition 
deficits and PPI deficits. Chronic administration of 5 mg/kg CBD instigated 
exploration in the dark zone of the light dark test but did not affect motor function or 
spatial learning and memory and did not reverse PPI deficits evident in transgenic 
females. Importantly, 5 mg/kg CBD reversed novel object recognition deficits in 
APPxPS1 transgenic females suggesting a therapeutic-like effect in this established 
mouse model for AD. Future research into the molecular effects of CBD should be 
considered, as well as investigating other doses and age of test animal. In conclusion, 
this study suggests that CBD has therapeutic value for particular behavioural 
impairments present in AD patients.  
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